Podcasts about Western University

On October 9, 1975, CBC listeners across the country heard David Suzuki introduce the very first episode of Quirks & Quarks. 50 years and thousands of interviews later, Quirks is still going strong, bringing wonders from the world of science to listeners, old and new.On October 7, 2025 we celebrated with an anniversary show in front of a live audience at the Perimeter Institute for Theoretical Physics in Waterloo, Ontario. We had guests from a range of scientific disciplines looking at what we've learned in the last 50 years, and hazarding some risky predictions about what the next half century could hold. Our panelists were:Evan Fraser, Director of Arrell Food Institute and Professor of Geography at the University of Guelph, co-chair of the Canadian Food Policy Advisory Council, a fellow of the Pierre Elliot Trudeau foundation, and a fellow of the Royal Canadian Geographical Society.Katie Mack, Hawking Chair in Cosmology and Science Communication at the Perimeter Institute for Theoretical Physics.Luke Stark, Assistant Professor in the Faculty of Information & Media Studies at Western University in London, Ontario, and a Canadian Institute for Advanced Research Azrieli Global Scholar with the Future Flourishing Program.Laura Tozer, Assistant Professor of Environmental Studies at the University of Toronto and director of the Climate Policy & Action Lab at the Department of Physical and Environmental Sciences at the University of Toronto Scarborough.Ana Luisa Trejos, a professor in the Department Electrical and Computer Engineering and the School of Biomedical Engineering and Canada Research chair in wearable mechatronics at Western University in London, Ontario.Yvonne Bombard, professor at the University of Toronto and scientist and Canada Research Chair at St. Michael's Hospital, Unity Health Toronto, where she directs the Genomics Health Services Research Program.

Scientists detect for the first time an unknown source of GPS interference coming from space. Also, as AI begins to design more and more DNA sequences being manufactured synthetically, how can those manufacturers be sure that what their customers are asking for will not produce toxic proteins or lethal weapons? And… how camera traps in polish forests reveal that the big bad wolf is more scared of humans than anything else. For that last few years instances of deliberate jamming and interference of GNSS signals has become an expected feature of the wars the world is suffering. Yet this disruption of the signals that all of us use to navigate and tell the time nearly always emanate from devices on the ground, or maybe in the air. But in ongoing research reported recently by Todd Humphreys of University of Texas at Austin and colleagues around the world is beginning to reveal that since 2019 an intermittent yet powerful signal has been causing GPS failures across Europe and the North Atlantic. The episodes have been thankfully brief so far, but all the signs suggest it comes not from soldiers or aeroplanes, but from a distantly orbiting satellite somewhere over the Baltic Sea. It may not be malevolent, it could be a fault, but the net of suspicion is tightening. A team of scientists including some from Microsoft report today in a paper in the journal Science an investigation to try to strengthen the vetting of synthetic DNA requests around the world. As AI-designed sequencies increase in number and application, the factories that produce the bespoke DNA are in danger of making and supplying potentially dangerous sequences to customers with malicious intents. But how do you spot the bad proteins out of the almost infinite possible DNA recipes? Tessa Alexanian of the International Biosecurity and Biosafety Initiative for Science, and one of the authors explains some of the thinking. Finally, Liana Zanette of Western University in Ontario and colleagues have been hanging around in Polish forests scaring wolves. Why? Because as wolf numbers rise in protected reserves, more and more human-wolf interactions occur. And a suspicion has arisen that the legal protection they enjoy has led to them losing their fear of humans in a dangerous way. Not so, says Liana's team, blowing away the straw arguments and setting fire to the political motivation to reduce their protection status. Wolves are still terrified of Nature's apex predator – us. Presenter: Roland Pease Producer: Alex Mansfield Production Coordinator: Jana Bennett-Holesworth (Image: Simulation screen showing various flights for transportation and passengers. Credit: Oundum via Getty Images).

Joseph McGill Jr. is the founder of the Slave Dwelling Project and made his first visit to Canada by coming to London on Sept. 29. Joseph spoke at Western University and visited the African Methodist Episcopal Church. He spoke with 980 CFPL's Mike Stubbs on London Live.

This recording features audio versions of the October 2025 Journal of Vascular and Interventional Radiology (JVIR) abstracts:ArticlesEffectiveness of Transjugular Intrahepatic Portosystemic Shunt Creation for the Treatment of Hepatopulmonary Syndrome ReadAdverse Events of Tunneled Central Venous Catheters versus Totally Implantable Venous Access Devices in Pediatric Oncology: A Systematic Review and Meta-analysis ReadGenicular Artery Embolization Using Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Prospective Study ReadThe Impact of Common-to-External Iliac Arterial Diameter Ratio on Mid- to Long-term Patency of Kissing Aortoiliac Stents ReadPrediction of Recurrence of Hepatocellular Carcinoma Following Radiation Segmentectomy with Resin Microspheres Based on Underdosed Tumor Volume on Yttrium-90 Positron Emission Tomography/CT Dosimetry ReadUndertreated Volume and Tumor Morphology as Predictors of Outcome Following Thermal Ablation of 3–7-cm Hepatocellular Carcinoma ReadRadiofrequency Ablation in the Management of Extensive Multinodular Goiter: A Midterm Single-Center Experience ReadJVIR and SIR thank all those who helped record this episode. To sign up to help with future episodes, please contact our outreach coordinator at millennie.chen.jvir@gmail.com. HostSonya Choe, University of California Riverside School of MedicineAudio EditorSonya Choe, University of California Riverside School of Medicine Outreach CoordinatorMillennie Chen, University of California Riverside School of Medicine Abstract Readers:Tiffany Nakla, Touro University Nevada College of Osteopathic Medicine, NevadaEmily Jagenberg, Oakland University. William Beaumont School of Medicine Ahmed Alzubaidi, Wayne State University School of MedicineClare Necas, Western University of Health SciencesMeghna Kolli, University of California Riverside School of MedicineSelena Yao, Wright State University Boonshoft School of MedicineShobhit Chamoli, Armed Forces Medical CollegeRead more about interventional radiology in IR Quarterly magazine or SIR's Patient Center. Support the show

BUFFALO, NY - September 24, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on September 22, 2025, titled “Loss of Trp53 results in a hypoactive T cell phenotype accompanied by reduced pro-inflammatory signaling in a syngeneic orthotopic mouse model of ovarian high-grade serous carcinoma.” In this study, led by first author Jacob Haagsma and corresponding author Trevor G. Shepherd from the Verspeeten Family Cancer Centre and Western University, Canada, researchers investigated how the loss of Trp53 – a critical tumor suppressor gene – affects immune responses in ovarian cancer. The team found that deleting Trp53 led to more aggressive tumor growth and a weaker immune response. These findings help explain why some ovarian tumors may be resistant to immunotherapy and point to new ways to improve treatment. High-grade serous ovarian carcinoma (HGSC) is a deadly cancer that is often diagnosed at a late stage. Immunotherapy, which enhances the body's immune system to fight cancer, has shown limited effectiveness in treating this type of cancer. To better understand why, the researchers developed a mouse model that closely mimics human HGSC. They injected ovarian epithelial cells, with and without Trp53, into the fallopian tubes, the origin site of most ovarian cancers. “In this study, we developed a syngeneic model reflecting both the site of origin and the genotype of early HGSC disease by deleting Trp53 in mouse oviductal epithelial (OVE) cells.” Mice injected with cells lacking Trp53 developed faster-growing and more invasive tumors, reflecting how the disease typically progresses in humans. These tumors also had fewer active T cells, which are immune cells responsible for attacking cancer. Moreover, the T cells that were present appeared less capable of responding to the tumor, creating an immune environment that allowed cancer to grow uncontrolled. Further analysis revealed that tumor cells without Trp53 had reduced activity in genes related to inflammation. These changes were associated with lower levels of key proteins that normally help immune cells detect and attack tumor cells. When the researchers collected tumor cells from the abdominal fluid of the mice—a condition that simulates advanced-stage disease—they observed even lower immune signaling than before. This suggests that as the tumor spreads, it becomes better at evading the immune system. This study highlights how early genetic mutations can shape the interaction between tumors and the immune system. In particular, the loss of Trp53 appears to trigger a chain of events that weakens immune surveillance and accelerates tumor progression. These findings emphasize the need to consider both genetic mutations and the tumor environment when designing immunotherapies for ovarian cancer. Understanding how genes like Trp53 influence immune behavior may lead to more effective treatments and help identify which patients are most likely to benefit from immunotherapy. DOI - https://doi.org/10.18632/oncotarget.28768 Correspondence to - Trevor G. Shepherd - tshephe6@uwo.ca Abstract video - https://www.youtube.com/watch?v=WFQw0psuC3M Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28768 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Canadian real estate investing is broken — the old playbook doesn't work anymore. In this new mini-series, I'm back after more than a year to cut through the noise and show you exactly what's changed, why Canada's market is stuck, and where the real opportunities are now.This series is all about why Canadian investors are increasingly pivoting to the U.S. With shrinking margins at home, mounting regulatory challenges, and disappearing cash flow, I'll show you how strategies like subject-to financing, double closes, and land flips south of the border create opportunities that simply don't exist in Canada. I'm diving deep into the deals I'm doing right now — real numbers, real strategies, and real results. From subject-to transactions to off-market acquisitions, I'll share how we're finding properties at steep discounts — sometimes 40 to 50 cents on the dollar — and why cash flow is still alive and well in the U.S. I'll also walk you through how to set up properly as a Canadian investor, avoid double taxation, and build a system that works even without setting foot on the properties. If you're a Canadian investor who's feeling stuck or frustrated, this series is for you. It's not as complicated as it looks once you know the playbook — and I'm here to share it. So make sure you're subscribed and stay tuned, because I'm just getting started.Disclaimer: This episode, as with every episode of this show, should NOT be considered as advice. Investment advice is NEVER given on this show. Always consult a competent investment advisor before making an investment decision.---Andrew Hines is a seasoned real estate investor, business-builder, educator, and podcast host, well-recognized for his extensive experience in the field. Andrew graduated with an HBA from the Richard Ivey School of Business in 2008 and spent three years teaching introductory business at Western University as a Lecturer. He has been investing in real estate since 2011 and completing value-add projects since 2015, primarily in the luxury student rental space. Andrew started a project management company for building out new-construction townhomes in 2016 and has since built over 50 residential units throughout Southwestern Ontario. Andrew is an advocate for treating real estate investing like a business and uses his experience in his educational endeavors, coaching numerous investors on strategies to achieve financial independence and scale their portfolios effectively.FOLLOW ON SOCIALS:Instagram: https://www.instagram.com/theandrewhinesFacebook: https://www.facebook.com/theandrewhinesTwitter: https://twitter.com/theandrewhinesLinkedIn: http://www.linkedin.com/in/theandrewhinesTikTok: https://www.tiktok.com/@therealandrewhines

It's YOUR time to #EdUpPCO In this episode, YOUR guest is Paul LeBlanc YOUR host is Amrit Ahluwalia⁠⁠, Executive Director of Continuing Studies at Western University in London, Ontario, Canada.Some key questions we tackle:·      How is the rapid evolution of AI technology transforming the nature of human-specific skills and work?·      What can universities do to help students keep pace with the changing labour market?·      How is the constant transformation in human-specific work impacting the need for continuous learning?Listen in to #EdUp! Thank YOU so much for tuning in. Join us on the next episode for YOUR time to EdUp!Connect with YOUR EdUp Team - ⁠⁠⁠⁠Elvin Freytes⁠⁠⁠⁠ & ⁠⁠⁠⁠Dr. Joe Sallustio⁠⁠⁠⁠Join YOUR EdUp community at ⁠⁠⁠⁠The EdUp Experience⁠⁠⁠⁠!We make education YOUR business!

Arleen Paré stops by to chat about her latest poetry collection, encrypted. Andrew asks about Coleridge and video games. It's a fun time!Arleen Paré is a writer with ten collections of poetry, based in Victoria, BC. She has been short-listed for the BC Dorothy Livesay Award for Poetry and has won the American Golden Crown Award for Poetry, the Victoria Butler Book Prize, a CBC Bookie Award, and a Governor Generals' Award for Poetry.Andrew French is a poet from North Vancouver, British Columbia. They have published three chapbooks, most recently Buoyhood (Alfred Gustav Press, 2025). Andrew holds a BA in English from Huron University College at Western University and an MA in English from UBC. They have hosted this podcast since 2019.

Dr. Al Grauer hosts. Dr. Albert D. Grauer ( @Nmcanopus ) is an observational asteroid hunting astronomer. Dr. Grauer retired from the University of Arkansas at Little Rock in 2006. travelersinthenight.org From April 2025. Today's 2 topics: - Greg Leonard was observing with our team's 60 inch telescope on Mt. Lemmon in Arizona when he discovered a relatively large space rock, 2017 FD157, which can theoretically come closer to the Earth's surface than the communications satellites! - Dr. Paul Wiegert of Western University in Canada, led a team of astronomers who have determined that 2015 BZ509, a 2 mile diameter object, bucks the solar system traffic by traveling in a direction backwards to all of the planets!   We've added a new way to donate to 365 Days of Astronomy to support editing, hosting, and production costs.  Just visit: https://www.patreon.com/365DaysOfAstronomy and donate as much as you can! Share the podcast with your friends and send the Patreon link to them too!  Every bit helps! Thank you! ------------------------------------ Do go visit http://www.redbubble.com/people/CosmoQuestX/shop for cool Astronomy Cast and CosmoQuest t-shirts, coffee mugs and other awesomeness! http://cosmoquest.org/Donate This show is made possible through your donations.  Thank you! (Haven't donated? It's not too late! Just click!) ------------------------------------ The 365 Days of Astronomy Podcast is produced by the Planetary Science Institute. http://www.psi.edu Visit us on the web at 365DaysOfAstronomy.org or email us at info@365DaysOfAstronomy.org.

Episode 203: Microinduction and harm reduction in OUD.  Nathan Bui and Sanjay Reddy describe how to manage opioid use disorder (OUD) by using microinduction and harm reduction, strategies that are reshaping the way we treat opioid use disorder. Written by Sanjay Reddy, OMSIV and Nathan Bui, OMSIV. Western University of Health Sciences, College of Osteopathic Medicine of the Pacific.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.IntroWelcome to episode 203 of Rio Bravo qWeek, your weekly dose of knowledge.Today, we're tackling one of the biggest health challenges of our time: opioid use disorder, or OUD. Nearly every community in America has been touched by it: families, friends, even healthcare providers themselves. For decades, treatment has been surrounded by barriers, painful withdrawals, stigma, and strict rules that often do more harm than good. Too many people who need help never make it past those walls. But here's the hopeful part, new approaches are rewriting the story. They are less about rigid rules and more about meeting people where they are. Two of the most promising strategies for treatment of OUD are buprenorphine microinduction and harm reduction. Let's learn why these two connected strategies could change the future of addiction recovery. Background information of treatment: The X-waiver (short for DATA 2000 waiver) was a special DEA requirement for prescribing buprenorphine for opioid use disorder. Doctors used to take extra training (8 hours) and apply for it. Then, they could prescribe buprenorphine to a very limited number of patients. The X-waiverhelped regulate buprenorphine but also created barriers to access treatment to OUD. It was eliminated in January 2023 and now all clinicians with a standard DEA registration no longer need a waiver to prescribe buprenorphine for OUD. Why buprenorphine?Buprenorphine is one of the safest and most effective medications for opioid use disorder. It has some key attributes that make it both therapeutic and extremely safe: 1) As a partial agonist at mu-opioid receptors, it binds and provides enough partial stimulation to prevent cravings and withdrawal symptoms without producing strong euphoria associated with full agonists. 2) Because it has a strong binding affinity compared to full agonists, it easily displaces other opioids that may be occupying the receptor. 3) As an antagonist at kappa-opioid receptors, it contributes to improved mood and reduced stress-induced cravings. 4) The “ceiling effect”: increasing the dosage past a certain point does not produce a stronger opioid effect. This ceiling effect reduces the risk of respiratory depression and overdose, making it a safer option than full agonists. 5) It also had mild analgesic effects, reducing pain. 6) Long duration of action: The strong binding affinity and slow dissociation from the mu-opioid receptor are responsible for buprenorphine's long half-life of 24–60 hours. This prolonged action allows for once-daily dosing in medication-assisted treatment for OUD. Induction vs microinduction:The problem is, starting it—what's called “induction”—can be really tough. Patients usually need to stop opioids and go through a period of withdrawal first. Drugs like fentanyl, which can cause precipitated withdrawal —a sudden, severe crash may push people back to using opioids. Because buprenorphine binds so tightly to the mu-opioid receptor, it can displace other opioids, such as heroin or methadone. If buprenorphine is taken while a person still has other opioids in their system, it can trigger sudden and severe withdrawal symptoms.Opioid withdrawal sign sand symptoms:Opioid withdrawal symptoms are very uncomfortable; patients may even get aggressive during withdrawals. As a provider, once you meet one of these patients you never forget how uncomfortable and nasty they can be. The symptoms are lacrimation or rhinorrhea, piloerection "goose flesh," myalgia, diarrhea, nausea/vomiting, pupillary dilation, photophobia, insomnia, autonomic hyperactivity (tachypnea, hyperreflexia, tachycardia, sweating, hypertension, hyperthermia), and yawning. Think about all the symptoms you run for COWS (Clinical Opiate Withdrawal Scale). It is estimated 85 % of opioid-using patients who inject drugs (PWID) reported opioid withdrawal. Fortunately, even though opioid withdrawal is very uncomfortable, it is not life-threatening (unlike alcohol or benzodiazepine withdrawal, which can be fatal).Many patients who start the journey treating opioid use disorder experience “bumps in the road” --they avoid treatment or drop out early. What is Microinduction? Microinduction is a fairly new strategy started in Switzerland around 2016. It is also known as the “Bernese method” (named after the city of Bern, Switzerland). With this method, instead of stopping opioids cold turkey, patients start with tiny doses of buprenorphine—fractions of a milligram. These doses gradually increase over several days while the patient continues their regular opioid use. While they begin this titer, they can continue use of the full agonist they were previously using–methadone, fentanyl, or heroin, while the buprenorphine begins to take effect. Once the buprenorphine builds up to a therapeutic level, the full agonist is stopped. This method uses buprenorphine's unique pharmacology to stabilize the brain's opioid system without triggering those really nasty withdrawal symptoms.Early studies and case reports suggest this is safe, tolerable, and effective method to do. Microinduction is changing the game, and it has been spreading quickly in North America. Instead of forcing patients to stop opioids completely, the dose is slowly increased over the next three to seven days, while the patient keeps using their usual opioids.By the end of that week, the buprenorphine has built up to a therapeutic level and the full agonist is stopped. The difference is really dramatic. Instead of a painful crash into withdrawal, patients describe the process as a gentle step down, or a ramp instead of a cliff. It's a flexible method. It can be done in a hospital, a clinic, or even outpatient with good follow-up. Once a patient and doctor develop a strong relationship built on the principles of patient autonomy and patient-centered care, microinduction can be closely monitored on a monthly basis including televisits. Microinduction has been shown to help more patients stay in treatment. The Role of Harm Reduction Instead of demanding perfection, harm reduction focuses on best practices providers can implement to reduce risk and keep patients safe. Harm reduction can vary from providing naloxone to reverse overdoses, giving out clean syringes, or offering safer injection education. It also means allowing patients to stay in treatment even if they keep using other substances, and tailoring care for groups like adolescents, parents, or people recently released from incarceration. Harm reduction says that instead of demanding perfection, let's focus on progress. Instead of all-or-nothing, let's devote resources to keeping people alive and safe. As mentioned,an option is providing naloxone kits so overdoses can be reversed in the moment. Also, giving out clean syringes so the risk of HIV or hepatitis infection is reduced while injecting heroin. Another way to reduce harm is teaching safer injection practices so people can protect themselves until they're ready for that next step in their treatment. It also means keeping the doors open, even when patients slip. If someone is still using other substances, they still deserve care. And it means tailoring support for groups who oftentimes get left behind. For people like adolescents, parents balancing childcare, or people coming out of incarceration who are at the highest risk of overdose. Harm reduction recognizes that recovery isn't a straight line. It's about meeting people where they are and walking with them forward. Conclusion:Microinduction is itself a harm reduction strategy. It lowers barriers by removing the need for painful withdrawal.When paired with a harm reduction culture in clinics, patients are more likely to enter care, stay engaged, and build trust with doctors for continued care. Managing opioid use disorder is one of the greatest health challenges of our time. But solutions like buprenorphine microinduction and harm reduction strategies are reshaping treatment—making it safer, more humane, and more accessible. If we embrace these approaches, we can turn barriers into bridges and help more people find recovery. Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you. Send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Bluthenthal, R. N., Simpson, K., Ceasar, R. C., Zhao, J., Wenger, L., & Kral, A. H. (2020). Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs. Drug and Alcohol Dependence, volume 211, 1 June 2020, 107932. https://doi.org/10.1016/j.drugalcdep.2020.107932.De Aquino, J. P., Parida, S., & Sofuoglu, M. (2021). The pharmacology of buprenorphine microinduction for opioid use disorder. Clinical Drug Investigation, 41 (5), 425–436. https://doi.org/10.1007/s40261-021-01032-7. Taylor, J. L., Johnson, S., Cruz, R., Gray, J. R., Schiff, D., & Bagley, S. M. (2021). Integrating harm reduction into outpatient opioid use disorder treatment settings. Journal of General Internal Medicine, 36 (12), 3810–3819. https://doi.org/10.1007/s11606-021-06904-4.Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/. 

Dr. Adam Power, co-founder and Chief Medical Officer at Front Line Medical Technologies, shares his fascinating journey from a background in vascular surgery to developing COBRA-OS, a groundbreaking device for hemorrhage control. He discusses the challenges and milestones in bringing this life-saving technology to market, the impact of the device in trauma and emergency care, and innovative future applications, including its unexpected use in non-traumatic cardiac arrest.    Guest links: https://frontlinemedtech.com/ Charity supported: Canadian Cancer Society Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 064 - Dr. Adam Power [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and today I'm excited to introduce you to my guest, Dr. Adam Power. Dr. Power is a leader in innovative medical devices for trauma and emergency care that is committed to lowering the barriers and bleeding control and resuscitation. Dr. Power was instrumental in the development of COBRA-OS, drawing on his unique clinical viewpoint and expertise to ensure utmost patient safety and assist with the company's global expansion. In addition to his current role as co-founder and Chief Medical Officer at Front Line Medical Technologies Incorporated, Dr. Adam Power is a vascular surgeon in the division of vascular surgery at Western University, which he joined in the fall of 2012, and he is involved in all aspects of academics and clinical care. Also, Front Line was just named the 2025 Medical Device Technology Company of the Year, so I definitely wanted to highlight that too. All right. Well, thank you so much for being here today, Adam. I'm so delighted to speak with you. [00:01:55] Dr. Adam Power: Yes, it's a pleasure to be here. Thank you. [00:01:57] Lindsey Dinneen: Of course. Well, I'd love if you would start by sharing a little bit about yourself, your background, and what led you to what you're doing today. [00:02:05] Dr. Adam Power: Sure, I'd love to. So I'm a Canadian. I grew up on the east coast of Canada and was always interested in science and math and those types of things. I think, importantly, I grew up with an identical twin brother as well. So we really didn't know what we wanted to do with our lives, and ultimately we're good in science and math and ended up in medicine. And then both of us, when we got into medicine, we weren't sure exactly what we wanted to do in medicine, and ultimately both of us became surgeons. He became a urology surgeon, and I became a vascular surgeon, where we joke that we're both plumbers. I deal with the red stuff and he's the yellow stuff. But I did my initial medical school out on the east coast of Canada and then I did my general surgery training, which also involved trauma training, and then did a Master's of Bioscience Enterprise, which was basically biotech business from the University of Cambridge in the UK. When I finished my general surgery training, I continued on and did vascular surgery training at Mayo Clinic down in the US, and since that time after graduating from there, I've been at Western University in London, Ontario, Canada, for the past 13 years practicing as a vascular surgeon and an academic vascular surgeon. But when I was here at Western, I was always interested in innovation. I filed my first patent as a resident way back when, and have filed many over the years. But ultimately, if I was ever gonna see anything that came outta my head and was actually used in a patient or I could actually use in a patient, I figured I'd have to do it. I knew that I couldn't do it by myself. And so, I was very fortunate to meet my co-founder Dr. Asha Parekh. She's a PhD, biomedical engineer, extremely smart jack of all trades, and we teamed up now about eight years ago. We met here at Western, teamed up and really took an idea right out of our heads and patented it and raised money for it, prototyped it, brought it all through the regulatory steps to approvals, built a quality system and ultimately got it out onto the market in Canada, US, Europe, now Australia, and more to come. So the commercialization piece is what we've been focusing on over the past three years. And it's been really fun, but very exhausting but very rewarding as well. I think I'll stop there because I've been blathering on, but... [00:04:39] Lindsey Dinneen: No, it's fantastic. I really appreciate it. Plus, it's really fun to hear about your trajectory and so, okay, so you've teased us a little bit about this company of yours and this innovation of yours. Can you now share a little bit more about that and the development of it over time? [00:04:55] Dr. Adam Power: Yes, of course. Well, I mean, thing that we recognized early on is, and I'll just explain how I normally explain it, is if you have bleeding, it's a hemorrhage control device. And so if you have bleeding in your extremities, then you can often either put pressure on it or you can put a tourniquet on it. The problem when you have internal bleeding in the torso is that you can't actually put direct pressure on it, and there's no tourniquet that necessarily works for intraabdominal, intrathoracic bleeding. And when people bleed to death before coming to hospital, I mean, they're bleeding in these areas. You can empty almost your entire blood volume into your chest or into your abdomen. And this does account for a significant number of fatalities in all environments, basically in the trauma environment. That's military, that's pre-hospital, that's any time that that people are bleeding from internal organs. And so, because this is such a problem, the old fashioned way to fix it is to open up someone's chest and put a clamp on the aorta. So what does that do? Is it basically above the clamp, keeps blood flowing. The remaining blood in the body keeps blood flowing to the brain and the heart, keep you alive. And then below the clamp, it stops sort of the hemorrhaging from the spleen or the liver or whatever. So there's two things going on. One above the clamp and two below the clamp. But opening up somebody's chest in, you know, side of the road or in the emergency department really is impossible. You need highly skilled people like vascular surgeons like myself to be able to do this. And even if we were at the side of the road, we don't have the resources available to keep a patient alive. So there is this idea that we could do this minimally invasively, sort of accomplish this through minimally invasive means. And this, the idea of doing REBOA, which is an acronym-- Resuscitative Endovascular Balloon Occlusion of the Aorta-- came into being. This was probably 15, 20 years ago now. It wasn't necessarily a new idea. It had been done since the Korean War. There was somebody actually put a balloon up into someone's aorta to stop bleeding, but it came back again and was starting to be used a little bit more because. And so really the idea is to, through the femoral artery in your groin where you can feel a pulse, you introduce initially a sheath, which is your access point, and then you place the device up through the sheath, up into the aorta and inflate a balloon in the aorta. So instead of an external clamp, it's an internal balloon clamp that keeps blood flowing above the balloon and stops the blood flowing from below the balloon. Initially these devices were as big as my baby finger, like they were massive. And so if you put them in and you took it out, there was a big hole in the artery, had to cut down on the artery and repair the artery. But as it got more and more advanced and technology advanced, they become smaller and smaller. So that's really where we came in. The initial devices were 12 French, about the size of my baby finger. And then it advanced to Seven French and all of a sudden Seven French-- and these are diameter, French sizes are basically diameter-- and so when it went from 12 to seven French, now we could start doing it through the skin without actually cutting down on the artery. But that Seven French size was still very large and you're putting this in the hands of people that don't do this all the time. And so, we had the idea to bring it down even further now to Four French. And so this is essentially the size of an IV. And so you put a tiny little IV in somebody's femoral artery. And lots of different people can do that. And then you advance the device up in, inflate the balloon and you can magically occlude the aorta. In our first study that we did, the first inhuman study, we averaged about just over a minute to occlude someone's aorta, which was really fast to be able to get that amount of control that quickly. So that, that was really been the advancement is to decrease the access size, make this whole procedure simpler so that so that we can essentially save more lives. [00:09:08] Lindsey Dinneen: Okay, so thank you so much for sharing a little bit about that. Can you tell me about the beginnings of this innovation and how you brought it to market? Because it's really wonderful to hear all the success, and I'm so excited to hear that it's spreading, you have presence all over the place now. But you know, that's not an easy pathway. And I'm curious if you could walk us through a little bit about that decision to go, "You know what? We have a solution to a known problem, we can make this happen." And then how did you actually go about doing that? [00:09:42] Dr. Adam Power: Yeah. I think, I mean, I make it sound fairly straightforward, like a nice story, but it certainly was not that. I mean, we were very lucky I would say, that we had a lot of great advisors and mentors that we figured that we try not to fail early, fail fast. We wanted to make this one as successful as possible. So before we made any decision, we often would consult our mentors. And I'm a surgeon. I like to shoot first, ask questions later. My partner is not. And so I think we, we strike an excellent balance between not just the engineering and clinical side of things, but also from driving a business forward, getting all the information, but helping to get decisions made and moving forward. You know, starting out, we really had to choose the right sort of fit for what we wanted to pursue. We like to say it checked all the boxes. It checked all the boxes as far as even where we are. We're in Canada, we're not in a tech triangle where there's tons of funding opportunities. We knew we would be limited from a funding perspective, so we couldn't choose something that necessarily required a hundred million dollars to start up. So, you know, we had this device that we knew that we could fundraise for it. And then once it was fundraised, it was simple enough that we could get it manufactured. We chose to go the OEM route for the original equipment manufacturer, so we didn't have to build a manufacturing facilities ourselves. And then really from there, and building a quality system in the regulatory, we did work with a lot of consultants, that was both positive and negative experience. We had great consultants. We had not so great consultants. But really what our our goal was, is to learn the process ourselves. And so there's always manuals for things, even from the FDA perspective. They give out great documentation about what is supposed to go into an FDA application. And we dug into that. We really tried to understand. We did not trust anyone. That's one of my rules in surgery is, "don't trust anyone, not even myself." So we really didn't trust our consultants, and we tried to double check and triple check everything so that we didn't make mistakes. And of course, we did make mistakes and had to go back to the drawing board a few times. But as much as we wanted to get this out there, we really did wanna learn the process and know the process because ultimately we're the ones that are responsible to the patients in the end, and we needed to make sure that we had a handle on each and every step of the way. We, of course, because of that, were maybe not as quick as we could have been but in other places we became more efficient because, as we learned the process, getting feedback back and doing it right the first time, it really made a difference. So. [00:12:39] Lindsey Dinneen: Yeah, absolutely. Of course. Yeah, and I appreciate you going into a little bit more of the nitty gritty details 'cause it is so fun to hear the success stories, but of course, as you go along, there's that pathway to success. And it's helpful to understand that yeah, it's gonna be potentially a long road, sometimes windy, sometimes weird, but at the same time that it is possible. So as you look to the future with your company, what are you thinking of in terms of the future? Are you going to continue down this pathway and continue with iterations of this device? Are you thinking of new devices to introduce as well? Or, what are your thoughts for the future? [00:13:18] Dr. Adam Power: Yeah. And I have to be very careful what I say here, obviously. I can share generically what our thoughts are. We love this. Ultimately there was no better feeling than to use-- I mean, I've used my device to save a patient. And, you know, I would say that Asha, who's my co-founder, she cares. I'm a physician, but she cares about the patients just as much as I do, as does everyone in our company, which is really quite rewarding. But the future, what does the future hold? We really want this to get to everywhere. Yes, we're in lots of different countries ,have commercialized really all around the globe, but we really wanna go deeper into a lot of these geographies and really help as many people as possible. We realize that we can't do it on our own and are gonna need help. And so that's, we're in a growth phase right now of our company and we're looking for strategic collaboration. We're looking for those opportunities to deepen our ties and in all the different geographies. That being said, we are inventors and of course we have an idea every day about what we could improve on. But as far as the pipeline goes for our company, we are focusing on some very specific up and coming applications that we hope to have in the next couple of years. And I also wanna say that, I talked about trauma and bleeding, but the more exciting side of aortic occlusion has really been the applications. And you'd think, okay, it makes sense for trauma to be able to stop blood flow and stop bleeding. But some of our recent successes have been through postpartum hemorrhage. And there is this really, terrible condition called placenta accreta, where the placenta grows into the uterus and when you deliver the baby either by C-section or by delivery, and then the placenta attempts to be delivered, it tears, and you can have torrential bleeding. And, and so our device is being used in these women who are pregnant when inflicted with this condition and helping to decrease blood transfusions, helping to save a mother's life. So that's been really amazing. And then next on the horizon is strangely there's, it's not even a bleeding application. We've done some research and there's research going on globally about using aortic, minimally invasive aortic occlusion for non-traumatic cardiac arrest. And so if, which is really, again, it's like, "Oh my gosh, does this thing do everything? It might make your supper tonight if you're not careful." So it, so what happens there is that if somebody drops dead basically in front of you, and you start CPR, if you start pushing on their chest and pushing on their heart, you're pushing blood to the whole body. And the way you get someone back to life is if you can get the heart muscle oxygenated again. So if you put an aortic occlusion balloon up close to the heart, every time you push, you're directing blood right into the coronary arteries and right into the brain as well. And so what we're seeing is that there's increased return of spontaneous circulation rates when you do this with CPR. And there are different trials around the world that if this shows that there's an increase in survival or in better neurological survival, this will be the first time that we've really changed the script on cardiac arrest since advanced cardiac life support came out many years ago. So this, again, is very exciting for a simple device to be able to make that much impact in all these different areas. So, you know, we have a lot to focus on right now, even growing into the future because some of these, like cardiac arrest, are quite early on. So we don't wanna lose sight of this great original product, but we do think all the time about different pipeline ideas that could help other patients. [00:17:18] Lindsey Dinneen: Yeah, but, and to your point, even the amazing other use cases for this incredible device, like you said-- maybe it's gonna make us dinner next-- but the idea being that, who knows? I mean, there's so much more to discover even now, which makes me excited just to think about how many more use cases you could have for it and how many more people you could save. So, speaking of that, are there any stories that kind of stand out to you, moments that you've had where, you know, either through your day job, so to speak, being a vascular surgeon, but also being the co-founder of this company that really sort of affirmed to you that, "You know what? I am in the right place at the right time, in the right industry." Just those moments that really stick with you. [00:18:05] Dr. Adam Power: Yeah, I mean, it obviously all stems back to the patient and what patients are impacted. And I remember, the first time that the device was used at our hospital, one of the radiologists called me in and said, " We need to use one of these balloon occlusion devices for a patient that's been in an accident." And so I went in and I said, "I actually have the device that my partner and I created. We can use this for the patient." And so we started using it for the lady that was involved in a very serious accident, had a pelvic fracture, and she was a Jane Doe at that particular time. She was anonymous. And anyway, we noticed that she had actually had some vascular surgery done based on her angiograms, and I leaned over and I-- so she was sedated, but she was awake-- I said, "Have you had vascular surgery? Who's your vascular surgeon?" And she said, "It's Dr. Power. He's such a nice man." And so I was actually helping one of my patients. That was pretty crazy. [00:19:04] Lindsey Dinneen: Oh. [00:19:05] Dr. Adam Power: Also from my hospital, when I heard one of my junior residents was able to save someone's life. So, you know, junior residents are often good, but they're not trained surgeons. And so to have a simplistic device that one of my residents could actually place and help someone, that's pretty amazing too. There's also been times where like even the postpartum hemorrhage, we hear the first cases in the States of saving mother and baby. That's pretty incredible. Or that we donated some devices to the Ukraine conflict as well, and we heard that it saved some soldiers' lives as well. And there's different military groups that, that use our device and save soldiers. So it's all back to the patient. And hearing those success stories and hearing about somebody alive because of this particular device, because of all this effort that we've put in. I mean, it's really makes it worthwhile. It sounds kind of corny, but as a surgeon, I can help one person at a time, but as somebody involved in industry and medical device industry, I don't even have to be there. You know, this device can help long after I'm gone. The tricky part of it, being the Chief Medical Officer is, I usually only have to worry about my patients. Now I have to worry about everybody worldwide and the device being used. That was a little hard to wrap my head around initially, but yeah. [00:20:28] Lindsey Dinneen: Yeah, of course. But the ripple, the ripples, the impact that you get to have because of this device and because of your diligence getting it to market, because it isn't an easy path, and that's incredible. So thank you for doing the work that you're doing. That's not easy and it's very appreciated. This is incredible. So, yeah. So, okay. When you were growing up, let's say 8-year-old, Adam-- you know, you're having a good time doing whatever you like to do-- could you possibly have pictured yourself where you are now? [00:21:08] Dr. Adam Power: No, I don't think so. I mean, I, I. I came from a very small, like, small upbringing and, you know, in my family I had absolutely lovely family members, but they really, apart from my aunt, they weren't overly educated. And so I really didn't know what it took to be successful in life, really. I had work ethic from my parents, that's for sure. And so that's what they bred into me. And all I knew is that I was gonna work as hard as I could, and I figured that as long as I keep working-- and I was lucky to have some brains as well-- then I figured things would fall into place. They honestly haven't fallen into place exactly how I pictured them as I grew older and what it would look like. But I'm certainly thankful for where I am right now, and what is the next five years or 10 years gonna look like? I have no idea. And I guess I just don't even picture it. I have goals, but I also know that those goals change depending on circumstances. And you need, as I'm growing into middle age-- I think I'm beyond middle age now-- I'm thinking about midlife crisis and things like that. I get into philosophy and there's like telic and atelic things and so, it's sounds, again, it's about the path and the journey. It's not about the ultimate goal because, having reached a lot of these successes, that good feeling lasts for maybe a day or half a day. And you think you know, I spent all these years coming with the, with our device, getting our device to market and getting FDA approval and like, oh my gosh, like, you'd think, I'd feel so great about that. And it did. It felt great, but you wake up the next day and you gotta keep going. So you have to enjoy the journey and that's really what it's the wisdom that comes with age is trying to enjoy the journey as much as possible and not focus too much beyond that. [00:23:09] Lindsey Dinneen: Yeah. Yeah, and I think that's really good advice too, in that it is because the daily life isn't usually all the celebration and successes. I mean, that does happen and those are good moments, but because the vast majority of our life is spent on the journey component of it, and going through those peaks and valleys, it is important to find something you love and feel that you can make an impact in. So I'm so thankful that this is what you've chosen to do. So pivoting the conversation a little bit just for fun, imagine that you're to be offered a million dollars to teach a masterclass on anything you want. Could be within your industry, but it doesn't have to be. What would you choose to teach? [00:23:55] Dr. Adam Power: And would that mean that I was an expert in it? [00:23:58] Lindsey Dinneen: Well, certainly if you're getting paid a million dollars, somebody has decided you aren't an expert at it. How about that? [00:24:05] Dr. Adam Power: Okay. Well. Can I pretend like I'm an expert in it? There's something that I really love, but I'm not I'm probably not an expert in it. It would be, I would teach a masterclass in DJing. Isn't that strange? I know it's so random. [00:24:21] Lindsey Dinneen: Oh my goodness! Tell me more! [00:24:23] Dr. Adam Power: Well, I mean, I love music. I've, I grew up playing lots of sports and never was involved in music. And, and I've always appreciated music and art, but I was never able to do it. And, you know, growing up I did love sort of all types of music and then even electronic music and it just somehow talked to me. So I started DJing electronic music basically when I was around med school and have always loved it now, and when I was over in England, I DJ'ed on the campus radio and also DJ'd in a club. It was really fun and it sounds pretty silly to be talking about this when I have these other things that are on the go. But honestly, being able to share space with other human beings these days, and actually having a good time and having it not be stressful and having it be only, you know, everybody's wishing others to have a good time. There's not many people that go out sort of dancing into electronic music that are thinking bad things about other people. Really they're just out for a good time. And so being able to steer that whole music and scene is pretty awesome. And I do love it. And I don't DJ as much as I used to, but I still do different events, usually Christmas parties for the operating room. I'll do the typically wedding sort of DJ, but then they always, 'cause they know me, they let me do an hour long electronic set, which is like hardcore electronic. But then I go back to the regular stuff. But I would want to teach a masterclass in DJing. [00:25:56] Lindsey Dinneen: That is awesome. How exciting. Oh my gosh, I love that. And I think you're right. Music brings us together and it's a wonderful way to, to share a little bit of joy. [00:26:07] Dr. Adam Power: Yeah. [00:26:08] Lindsey Dinneen: Yeah. Okay. And then how do you wish to be remembered after you leave this world? [00:26:15] Dr. Adam Power: I, so number one is I don't, again, with my midlife crisis, I've actually been trying to eliminate my ego as much as possible. And so when people talk about legacy, it actually gives me the hives these days to be quite honest, because I don't like that because I think you're focused a lot on yourself. In my opinion, a lot of legacy is all about you. The way that I would wanna be remembered, though, is truly that I was kind and compassionate to everyone that I met, and that I stood for something, and that I left the world a better place. [00:26:57] Lindsey Dinneen: Yeah, those are wonderful things to want to be remembered for, absolutely. And then final question, what is one thing that makes you smile every time you see or think about it? [00:27:09] Dr. Adam Power: My kids. My son Kai and my daughter Saoirse. They are the light of my life. And I, you would think that with how busy I am ,you know, those things would deprioritize, but they truly are the one thing in my life that makes me smile when I get up in the morning. [00:27:30] Lindsey Dinneen: Oh, that's wonderful. Well, that is absolutely incredible. I loved getting to meet you and speak with you a little bit today. Thank you so much for sharing about your journey. Thank you for sharing about your incredible device and your bits of wisdom along the way. The idea of we've gotta enjoy the experience, the path, the journey. And I just really appreciate you spending some time with us. So thank you for everything you're doing to change lives for a better world. [00:27:59] Dr. Adam Power: Oh, well, thank you for giving me the opportunity to speak with you. It was absolutely lovely chatting with you today. [00:28:05] Lindsey Dinneen: Wonderful. Well, thank you again so much. Thank you also to listeners who are tuning in, and if you're as inspired as I am, I would love it if you would share this episode with a colleague or two and we'll catch you next time. [00:28:20] Ben Trombold: The Leading Difference is brought to you by Velentium. Velentium is a full-service CDMO with 100% in-house capability to design, develop, and manufacture medical devices from class two wearables to class three active implantable medical devices. Velentium specializes in active implantables, leads, programmers, and accessories across a wide range of indications, such as neuromodulation, deep brain stimulation, cardiac management, and diabetes management. Velentium's core competencies include electrical, firmware, and mechanical design, mobile apps, embedded cybersecurity, human factors and usability, automated test systems, systems engineering, and contract manufacturing. Velentium works with clients worldwide, from startups seeking funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

Dr. Kate Moore grew up in Michigan but happily relocated to Southern California after gaining acceptance to Western University of Health Sciences. Since graduating in 2015, she has worked with exotics in several GPs, while learning acupuncture and laser therapy, until she opened her own house call practice in August of 2022.  Along with owning and operating Good Vibes Mobile Veterinary Services, she now also works as the primary veterinarian at the Santa Ana Zoo, where she promises NOT to steal any of the animals. Despite the workload, she also manages to find time to pursue her hobbies, some of which include sewing, watching football, painting D&D minis, kickboxing, going to Disneyland, taking her two rescue chihuahuas to the beach, and tending to her isopods. Topics covered in this episode:  Dr. Moore's journey into mobile house call practice Burnout and rediscovering passion Squirrel stories and wildlife care Understanding emotional processing & authenticity in veterinary practice The joy of snails Starting a mobile veterinary practice The House Call Vet Academy experience Links & Resources:  Visit the Good Vibes Mobile Veterinary Services website to learn more Find Dr. Moore on Instagram Find Dr. Moore on Facebook The House Call Vet Academy Resources:  Download Dr. Eve's FREE House Call & Mobile Vet Biz Plan Find out about the House Call Vet Academy online CE course Learn more about Dr. Eve Harrison Learn more about the Concierge Vet Mastermind Get your FREE Concierge Vet Starter Kit mini course Learn more about SoulShine Space For Vets. Use discount code SHINE15 for 15% OFF SoulShine Space For Vets! (Available for a limited time only! Rules and restrictions apply.) Learn more about 1-to-1 coaching for current & prospective house call & mobile vets Get House Call Vet swag Learn more about the House Call & Mobile Vet Virtual Conference Register TODAY for the House Call & Mobile Vet Virtual Conference, February 7th-8th, 2026!!!!!! Here's a special gift from me as a huge thank you for being a part of our wonderful House Call Vet Cafe podcast community! ☕️ GET 20% OFF your Four Sigmatic Mushroom Coffee when you order through this link! 4Sig truly is my favorite!!! Enjoy it in good health, my friends! Music:  In loving memory of Dr. Steve Weinberg.  Intro and outro guitar music was written, performed, and recorded by house call veterinarian Dr. Steve Weinberg.  Thank you to our sponsors!  Chronos  O3 Vets  This podcast is also available in video on our House Call Vet Cafe YouTube channel 

Send us a textMeet Dr. Ken Thai, PharmD—CEO of 986 Degrees Corporation (a pharmacy franchise), multi-site independent pharmacy owner across Southern California and Nevada, and Adjunct Assistant Professor of Pharmacy Practice at USC and Western University. A past president of CPhA (California Pharmacists Association) and current national VP at NCPA, he was honored with the 2022 NCPA Willard B. Simmons Independent Pharmacist of the Year. His career blends leadership, education, and entrepreneurship, always anchored to better patient care.In this conversation, we trace his path from a UCLA biology degree to a USC School of Pharmacy PharmD, followed by a Community Pharmacy Practice residency at USC. We dig into how he opened and scaled multiple independents—spanning long-term care, compounding, DME, infusion, and specialty—and why he built a franchise model to mentor and multiply pharmacist-owners. You'll hear how he designs training that sticks, builds culture across locations, and keeps teams focused on outcomes.We also talk about teaching and precepting: what pharmacy students need now, the mindset shift from clinician to owner, and practical steps to evaluate a market, choose services, and launch sustainably. Dr. Thai shares playbooks on onboarding, metrics that matter, quality systems, and how associations like CPhA and NCPA shape the future of independent pharmacy and pharmacy entrepreneurship.If you're a pharmacy student, new grad, independent owner, or healthcare entrepreneur, this episode is your blueprint for growth. Drop your questions in the comments, share with a colleague who's thinking about ownership, and subscribe for more SGV stories at the intersection of leadership, small business, and patient care. Keywords: independent pharmacy, pharmacy franchise, pharmacy ownership, pharmacy management, USC School of Pharmacy, Western University of Health Sciences, CPhA, NCPA, 986 Degrees, pharmacy entrepreneur.__________Music CreditsIntroEuphoria in the San Gabriel Valley, Yone OGStingerScarlet Fire (Sting), Otis McDonald, YouTube Audio LibraryOutroEuphoria in the San Gabriel Valley, Yone OG__________________My SGV Podcast:Website: www.mysgv.netNewsletter: Beyond the MicPatreon: MySGV Podcastinfo@sgvmasterkey.com

It's YOUR time to #EdUpPCO In this episode, YOUR guest is Shawn Miller YOUR host is Amrit Ahluwalia⁠⁠, Executive Director of Continuing Studies at Western University in London, Ontario, Canada.Some key questions we tackle:·      What are some of the top-of-mind considerations for onlinelearning leaders when thinking about the effective use of AI in education?·      How does our thinking around assessment need to evolve now that AI is so prevalent and accessible?·      What are some of the most common misconceptions higher ed faculty and leaders have about AI?Listen in to #EdUp! ThankYOU so much for tuning in. Join us on the next episode for YOUR time to EdUp!Connect with YOUR EdUp Team - ⁠⁠⁠⁠Elvin Freytes⁠⁠⁠⁠ & ⁠⁠⁠⁠Dr. Joe Sallustio⁠⁠⁠⁠Join YOUR EdUp community at ⁠⁠⁠⁠The EdUp Experience⁠⁠⁠⁠!We make education YOUR business!

Send us a textWelcome Back to Headfirst: A Concussion Podcast. Today we have the honour and privilege to be joined by Dr Matt Ventresca and Dr Kathryn Henne. Dr. Ventresca is a critical sports studies scholar and Research Associate at Western University and Brock University, as well as a Visiting Fellow at Australian National University. His decade-long research focuses on how social and cultural inequalities shape our understanding of brain injuries in sport, especially concussions and CTE, examining the roles of media, science, and public narratives. He has also held research positions at Georgia Tech and the University of Calgary.Professor Kathryn Henne directs the School of Regulation and Global Governance (RegNet) at ANU and is a leading expert in regulatory governance. Her work explores how science and technology influence health, safety, and social policy, with a special focus on concussion and CTE regulation. Dr. Henne has published over 76 academic articles, cited more than 1,700 times.  00:30 - Episode Introduction 01:30 - What is a Concussion, Repetitive Head Impacts and CTE?  06:30 - Biopsychosocial Models/ Qualitative Research with Concussion? 13:14 – What is Meant by Functionalism in Concussion? 19:05 - Concussion Across Gender 32:44 - CTE a defence for murder or A Criminal mind?  42:24 – Cultural Aspects of CTE 45:23 – Violent Impacts: How Power and Inequality Shape the Concussion Crisis   Dr Matt Ventresca:https://mattventresca.caGoogle Scholar: https://scholar.google.com/citations?user=L-UuJWkAAAAJ&hl=en Dr Kathryn Henne:https://katehenne.comGoogle Scholar: https://scholar.google.com/citations?user=PIyJCfAAAAAJ&hl=en  Books Violent Impacts: How Power and Inequality Shape the Concussion Crisis: https://www.amazon.com.au/Violent-Impacts-Inequality-Concussion-Crisis/dp/0520396987/ref=tmm_pap_swatch_0  Sociocultural Examinations of Sports Concussions:https://www.amazon.com.au/Sociocultural-Examinations-Sports-Concussions-Ventresca/dp/1032085320   Subscribe, review and share for new episodes which will drop weeklySocial media:Twitter: @first concussionFacebook: Headfirst: A concussion podcastInstagram: Headfirst_ Concussion  Email: headfirstconcussion@gmail.com

The name Terry Fox is synonymous with courage, perseverance and promise. After losing his leg at just 18 years old, his run across Canada inspired generations to come – and to date, has raised over $900 million for cancer research. His journey was deeply rooted in wanting to do more, by raising awareness and to help others see strength, not weakness. These same sentiments were true for George Hincks and Marshall McDougall, two Canadian men who both had a leg amputated as a result of injuries sustained in World War I. Their hike across our nation is a story you may not have heard - but once you do, you will never forget.Host Melanie Ng speaks with Eric Story, the author of a feature about George Hincks and Marshall McDougall. Eric is an adjunct professor at Wilfrid Laurier University and a postdoctoral fellow at Western University. We love feedback at The Big Story, as well as suggestions for future episodes. You can find us:Through email at hello@thebigstorypodcast.ca Or @thebigstoryfpn on Twitter

Dr. Kaitlyn Mendes of Western University spoke with Mike Stubbs about the new documentary on high school catfishing called "Unknown Number" and also gave her thoughts on parenting teens today.

Did you know that the questions we ask children should change as they develop? Asking the right questions at the right time helps children's communication flourish.Paula LaSala-Filangeri is a Speech-Language Pathologist who has been supporting children and families for over 25 years.How can parents move beyond flashcards and start turning everyday routines, like walking in nature or baking a cake, into powerful opportunities for language growth?Here are a few of the key insights we'll explore:

It's YOUR time to #EdUpPCO In this episode, YOUR guest is Priyo Chatterjee YOUR host is Amrit Ahluwalia⁠⁠, Executive Director of Continuing Studies at Western University in London, Ontario, Canada.Some key questions we tackle:·      Why is it so important for universities to be focused ondesigning cohesive and engaging learner experiences?·      What best practices can higher education leaders draw from the tech and eCommerce industries when designing great learner experiences?·      How are you and your colleagues leveraging AI tools todeliver cohesive and personalized learner experiences at scale?Listen in to #EdUp! Thank YOU so much for tuning in. Join us on the next episode for YOUR time to EdUp!Connect with YOUR EdUp Team - ⁠⁠⁠⁠Elvin Freytes⁠⁠⁠⁠ & ⁠⁠⁠⁠Dr. Joe Sallustio⁠⁠⁠⁠Join YOUR EdUp community at ⁠⁠⁠⁠The EdUp Experience⁠⁠⁠⁠!We make education YOUR business!

O documento "Domain of AI-Awareness for Education", da autoria de Dani Dilkes, da Western University, é um recurso abrangente que explora o impacto da Inteligência Artificial generativa na educação. Organizado em sete domínios – Conhecimento, Ética, Valores, Afeto, Habilidades, Pedagogia e Interconectividade – a obra oferece uma visão multifacetada da IA. Começa por explicar as fundações da IA generativa, incluindo como os Grandes Modelos de Linguagem funcionam e as suas limitações, como alucinações e preconceitos. Em seguida, aborda as considerações éticas, como privacidade, propriedade intelectual, direitos de autor, acessibilidade e impacto ambiental, apresentando ainda um enfoque baseado em valores para a integridade académica e a gestão das respostas emocionais à IA. Por fim, o recurso detalha as habilidades necessárias para utilizar a IA generativa, como a engenharia de prompts e a avaliação crítica dos resultados, e oferece orientações pedagógicas sobre a sua integração no ensino e na avaliação, distinguindo entre a substituição e o apoio à aprendizagem.

O podcast do livro "Domain of AI-Awareness for Education", da autoria de Dani Dilkes, da Western University, é um recurso abrangente que explora o impacto da Inteligência Artificial generativa na educação. Organizado em sete domínios – Conhecimento, Ética, Valores, Afeto, Habilidades, Pedagogia e Interconectividade – a obra oferece uma visão multifacetada da IA. Começa por explicar as fundações da IA generativa, incluindo como os Grandes Modelos de Linguagem funcionam e as suas limitações, como alucinações e preconceitos. Em seguida, aborda as considerações éticas, como privacidade, propriedade intelectual, direitos de autor, acessibilidade e impacto ambiental, apresentando ainda um enfoque baseado em valores para a integridade académica e a gestão das respostas emocionais à IA. Por fim, o recurso detalha as habilidades necessárias para utilizar a IA generativa, como a engenharia de prompts e a avaliação crítica dos resultados, e oferece orientações pedagógicas sobre a sua integração no ensino e na avaliação, distinguindo entre a substituição e o apoio à aprendizagem.

Every summer, Canadian scientists leave their labs and classrooms and fan out across the planet to do research in the field. This week, we're sharing some of their adventures.Camping out on a remote island with thousands of screaming, pooping, barfing birdsAbby Eaton and Flynn O'Dacre spent their summer on Middleton Island, a remote, uninhabited island that lies 130 kilometers off the coast of Alaska. They were there to study seabirds, in particular the rhinoceros auklet and the black-legged kittiwake, as a part of a long-term research project that monitors the health of the birds to help understand the health of the world's oceans. Eaton and O'Dacre are graduate students working under Emily Choy at McMaster University in Hamilton, OntarioDodging lions and mongooses to monitor what wild dogs are eating in MozambiquePhD student Nick Wright spent his summer in Gorongosa National Park in Mozambique. After a brutal civil war wiped out 95 per cent of the large mammals in the park, much work has been done to bring back a healthy wildlife population, to mixed success. Nick was monitoring wild dogs this summer to learn what they're eating, and what effects their recent re-introduction has had on the other animals. Wright is in the Gaynor lab at the University of British Columbia.Saving ancient silk road graffiti from dam-inundationThe legendary silk road is a network of trade routes stretching from Eastern China to Europe and Africa, used by traders from the second century BCE to the fifteenth century CE. Travelers often left their marks, in the form of graffiti and other markings on stone surfaces along the route. Construction of a dam in Pakistan is threatening some of these petroglyphs, and an international team is working to document them online while there is still time. Jason Neelis, of the Religion and Culture Department, and Ali Zaidi, from the Department of Global Studies, both at Wilfrid Laurier University in Waterloo, Ontario, are part of the team.Prospecting for World War II bombs in an Ottawa bogPablo Arzate's tests of sensor-equipped drones developed for mining uncovered 80-year-old relics leftover from World War II bomber pilot training in the Mer Bleue bog southeast of Ottawa. Arzate, the founder of 3XMAG Technologies from Carleton University, says his newly-developed technology revealed a trove of unexploded ordnance lurking beneath the bog's surface. Technology allows examination of Inca mummies without disturbing themAndrew Nelson and his team spent the summer in Peru devising new methods of non-invasively scanning Peruvian mummies dating to the Inca period – so they can study them without unwrapping them. In Peru, ancient human remains were wrapped in large bundles along with other objects. Nelson is a professor and chair of the Department of Anthropology at Western University in London, Ontario. This work is done in conjunction with the Ministry of Culture of Peru.Eavesdropping on chatty snapping turtles in Algonquin ParkSince 1972, scientists have been spending their summers at the Algonquin Park research station to monitor the turtles living in the area. In recent years, the researchers discovered that these turtles vocalise –– both as adults, and as hatchlings still in the egg. So this summer, Njal Rollinson and his students set out to record these vocalisations to try and understand what the turtles are saying. Rollinson is an associate professor in the Department of Ecology and Evolutionary Biology and the School of the Environment at the University of Toronto.

Welcome to another powerful episode of Resiliency Radio with Dr. Jill Carnahan, featuring integrative medicine expert Dr. Pejman Katiraei. In this conversation, we dive deep into the connections between Autism, mold exposure, and the microbiome, and how these factors influence overall health and chronic conditions.

Listen to ASCO's JCO Oncology Practice Art of Oncology article, "No Versus Know: Patient Empowerment Through Shared Decision Making” by Dr. Beatrice Preti, who is an Assistant Professor at Emory University. The article is followed by an interview with Preti and host Dr. Mikkael Sekeres. Dr Preti explores the challenges which may prevent oncologists from fully engaging with patients during shared decision making. TRANSCRIPT Narrator: No Versus Know: Patient Empowerment Through Shared Decision Making, by Beatrice T.B. Preti, MD, MMed, FRCPC  During a recent clinic, I saw three patients back-to-back, all from minority backgrounds, all referred for second opinions, all referenced in the notes for being different forms of difficult. Refused chemo, refused hospice, read one note. Refused surgery and chemo, read another, unsure about radiation. Yet, despite the documented refusals (I prefer the term, decline), they had come to my clinic for a reason. They were still seeking something. As an oncologist trained in a program with a strong emphasis on shared decision making between physician and patient, I approach such situations with curiosity. I consider optimal shared decision making a balance between the extremes of (1) providing a patient complete choice from a menu of treatment options, without physician input, and (2) indicating to a patient the best course of treatment, in the eyes of the physician.1 This is a balance between beneficence (which can often turn paternalistic) and patient autonomy and requires a carefully crafted art. Many of my consults start with an open question (Tell me about yourself…?), and we will examine goals, wishes, and values before ever touching on treatment options. This allows me to take the knowledge I have, and fit it within the scaffold of the patient in front of me. A patient emphasizing quantity of life at all costs and a patient emphasizing weekly fishing trips in their boat will receive the same treatment option lists, but with different emphases and discussions around each. Yet, many physicians find themselves tending toward paternalistic beneficence—logical, if we consider physicians to be compassionate individuals who want the best for their patients. All three patients I saw had been offered options that were medically appropriate, but declined them as they felt the options were not right for them. And all three patients I saw ended up selecting a presented option during our time together—not an option that would be considered the best or standard of care, or the most aggressive treatment, but an option that aligned most with their own goals, wishes, and values. This is of particular importance when caring for patients who harbor different cultural or religious views from our own; western medicine adopts many of its ideas and professional norms from certain mindsets and cultures which may not be the lenses through which our patients see the world. Even when a patient shares our personal cultural or religious background, they may still choose a path which differs from what we or our family might choose. It is vital to incorporate reflexivity in our practice, to be mindful of our own blinders, and to be open to different ways of seeing, thinking, and deciding. I will admit that, like many, I do struggle at times when a patient does not select the medically best treatment for themselves. But why? Do we fear legal repercussions or complaints down the road from not giving a patient the standard of care (often the strongest treatment available)? Do we struggle with moral distress when a patient makes a choice that we disagree with, based on values that we ourselves do not hold? Do we lack time in clinics to walk patients through different options, picking the method of counseling that allows the most efficiency in packed clinical systems? Is it too painful a reminder of our mortality to consider that, especially in the setting of terminally ill patients, aiming for anything other than a shot at the longest length of life might be a patient's preference? Or are we so burnt out from working in systems that deny us sufficient choice and autonomy (with regards to our own work, our own morals, and our own lives) that, under such repeated traumas, we lose touch with the idea of even having a choice? I have a number of patients in my clinic who transferred care after feeling caught between one (aggressive) treatment option and best supportive care alone. They come looking for options—an oral agent that allows them to travel, a targeted therapy that avoids immunosuppression, or a treatment that will be safe around dogs and small children. They are looking for someone to listen, to hold their hand, to fill in the gaps, as was told to me recently, and not skirt around the difficult conversations that both of us wish we did not have to have. Granted, some of the conversations are challenging—requests for ivermectin prescriptions, for example, or full resuscitation efforts patients with no foreseeable chance of recovery (from a medical standpoint) to allow for a possible divine miracle. However, in these cases, there are still goals, wishes and values—although ones that are not aligned with evidence-based medical practice that can be explored, even if they are challenging to navigate. As my clinic day went on, I spoke with my patients and their loved ones. One asked the difference between hospice and a funeral home, which explained their reluctance to pursue the former. Another asked for clarification of how one treatment can treat cancer in two different sites. And yet still another absorbed the information they requested and asked to come back another day to speak some more. All questions I have heard before and will continue to hear again. And again. There is no cure for many of the patients who enter my GI medical oncology clinic. But for fear, for confusion, perhaps there is. Cancer wreaks havoc on human lives. Plans go awry, dreams are shattered, and hopes are crushed. But we can afford some control—we can empower our patients back—by giving them choices. Sometimes, that choice is pitiful. Sometimes, it is an explanation why the most aggressive treatment option cannot be prescribed in good faith (performance status, bloodwork parametres), but it is a choice between a gentle treatment and no treatments. Sometimes it is a choice between home hospice and a hospice facility. I teach many of the learners who come through my clinic about the physician's toolbox, and the importance of cultivating the tools of one's specific specialty and area of work. For some (like surgeons), the tools are more tangible—physical skills, or even specific tools, like a particular scalpel or retractor. For others, like radiologists, it might be an ability—to recognize patterns, for example, or detect changes over time. For those of us in medical oncology, our toolbox can feel limiting at times. Although we have a handful of treatments tied to a specific disease site and histology, these often fall short of what we wish we could offer, especially when studies cite average survivals in months over years. But one of our most valuable tools—more valuable, I would argue, than any drug—is the communication we have with our patients, the way we can let them know that someone is there for them, that someone is here to listen, and that someone cares. Furthermore, the information we share—and the way we share it—has the potential to help shape the path that our patient's life will take moving forward—by empowering them with information to allow them to make the decisions best for them.2 Although having such conversations can be difficult and draining for the oncologist, they are a necessary and vital part of the job. My clinic team knows that we can have up to six, seven such conversations in the course of a half-day, and my clinic desk space is equipped for my between-patient routine of sips of tea and lo-fi beats, a precious few moments left undisturbed as much as possible to allow a bit of recharging. By finding a safe space where I can relax for a few moments, I can take care of myself, enabling me to give each of my patients the time and attention they need. When patients thank me after a long, difficult conversation, they are not thanking me for sharing devastating, life-altering news of metastatic cancer, prognoses in the order of months, or disease resistant to treatment. They are thanking me for listening, for caring, for seeing them as a person and affording the dignity of choice—autonomy. I have had patients make surprising decisions—opting for no treatment for locally-advanced cancers, or opting for gentle treatment when, medically, they could tolerate stronger. But by understanding their values, and listening to them as people, I can understand their choices, validate them, and help them along their journey in whatever way possible. Providing a choice affords a suffering human the right to define their path as long as they are able to. And we can give patients in such situations support and validation by being a guide during dark days and challenging times, remembering that medically best treatment is not always the best. When a patient says no to offered options, it does not (necessarily!) mean they are rejecting the expertise of the physician and care team. Rather, could it be a request to know more and work together with the team to find a strategy and solution which will be meaningful for them?   Mikkael Sekeres: Welcome back to JCO's Cancer Stories: The Art of Oncology. This ASCO podcast features intimate narratives and perspectives from authors exploring their experiences in oncology. I'm your host, Mikkael Sekeres. I'm Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami. Today we're joined by Beatrice Preti, Assistant Professor at Emory University, Adjunct Professor at Western University, and PhD candidate with Maastricht University, to discuss her JCO Oncology Practice article, "No Versus Know: Patient Empowerment Through Shared Decision-Making." At the time of this recording, our guest has no disclosures. Beatrice, thank you so much for contributing to JCO Oncology Practice and for joining us to discuss your article. Beatrice Preti: Well, thank you so much for having me today. Mikkael Sekeres: It's an absolute treat. I was wondering if we could start with sort of a broad question. Can you tell us about yourself? What was your journey like that landed you where you are right now? Beatrice Preti: Oh goodness, that's a very loaded question. Well, I am originally from Canada. I did all my training in Canada at a couple of different schools, McMaster, Queens, Western University. Before medicine, I was always interested in the arts, always interested in writing, always interested in teaching. So that's something that's really, I guess, come forth throughout my medical practice. During my time at Western, I trained as a gastrointestinal medical oncologist, so that's my clinical practice. But on the side, as you've noted, I've done some work in medical education, got my Masters through Dundee, and now doing my PhD through Maastricht in the Netherlands, which I'm very excited about. Mikkael Sekeres: That's fantastic. What's your PhD in? Beatrice Preti: Health Professions Education. Mikkael Sekeres: Wonderful - can never get too much of that. And can I ask, are you at the stage now where you're developing a thesis and what's the topic? Beatrice Preti: Yeah, absolutely. So the program itself is almost exclusively research based. So I'm thinking of more of a social psychology side, looking at impression management and moral distress in medical trainees, and really along the continuum. So what we're looking at is when people act in ways or feel that they have to act in ways that aren't congruent with what they're feeling inside, why they're doing that and some of the moral tensions or the moral conflicts that go along with that. So a good example in medicine is when you're with a patient and you have to put on your professional face, but inside you might be squirming or you might be scared or worried or anxious or hungry, but you can't betray that with the patient because that would be unprofessional and also unfair to the patient. Mikkael Sekeres: Wow, that's absolutely fascinating. How does that change over the course of training? So how does it change from being a medical student to a resident or fellow to a junior faculty member? Beatrice Preti: So I'm only one year into the PhD, so I don't have all the information on this as yet. Mikkael Sekeres: You don't have all the answers yet? What are you talking about? Beatrice Preti: Yeah, they're telling me I have to finish the PhD to get all the answers, but I think that we certainly are seeing some kind of evolution, maybe both in the reasons why people are engaging in this impression management and the toll it takes on them as well. But stay tuned. It might take me a couple of years to answer that question in full. Mikkael Sekeres: Well, I just wonder as a, you know, as a medical student, we go into medical school often for reasons that are wonderful. I think almost every essay for somebody applying to medical school says something about wanting to help people, right? That's the basis for what draws us into medicine. And I wonder if our definition of what's morally right internally changes as we progress through our training. So something that would be an affront to our moral compass when we start as a medical student may not be such an affront later on when we're junior faculty. Beatrice Preti: Yes, definitely. And I think there's a lot of literature out there about coping in the medical profession because I think that by and large, especially in the lay community, so premedical students, for example, but even within our own profession as well, we don't really give enough credence to the impact a lot of the things that we do or witness have on us personally. That lack of insight doesn't allow us to explore coping mechanisms or at least think things through, and oftentimes what we're seeing is a survival instinct or a gut reaction kick in rather than something that we've carefully thought through and said, you know, “These situations are stressful for me, these situations are difficult. How can I cope? How can I make this more sustainable for me, knowing that this is an aspect of medicine that really isn't escapable.” Mikkael Sekeres: What a fascinating topic and area to be studying. I can't wait for all of the findings you're going to have over the course of your career. But oncology is a field that's, of course, rife with these sorts of conflicts. Beatrice Preti: Yeah, definitely. Mikkael Sekeres: I'm curious if you can talk a little bit about your own story as a writer. You say you've always been a writer. How long have you been writing reflective pieces? Beatrice Preti: Oh, goodness. So there's certainly a difference between how long I've been writing reflective pieces and how long I've been writing good reflective pieces. I can vaguely remember, I think being perhaps 10 years old and writing in school one recess period, sort of both sides of a loose leaf piece of paper, some form of reflection that would have ended up straight in the rubbish bin. So that was probably when it started. Certainly in medical school, I published a fair bit of reflective writing, poetry. That continued through residency, now as a junior attending as well. Mikkael Sekeres: Well, you're excellent at it and I can't see any rubbish can that would accept your pieces for the future. If you feel comfortable doing so, can you tell us what prompted you to write this particular piece? Beatrice Preti: Yes. So this piece was written Friday night around 9:00, 10:00 at night, literally at the end of the clinic day that I described. Coming on the heels of talking about coping, I think for many people in medicine, writing is a coping mechanism and a coping strategy that can be quite fruitful and productive, especially when we compare it to other potential coping strategies. Sometimes it's certainly difficult to write about some of the things we see and certainly it's difficult sometimes to find the words. But on this particular night, the words came quite easily, probably because this is not an isolated incident, unfortunately, where we're seeing patients coming for second opinions or you're encountering patients or you're encountering people who you are not directly treating in your everyday life, who express frustrations with the health care system, who express frustrations with not feeling heard. I think all you have to do is open social media, Facebook, Reddit, and you'll see many, many examples of frustrated individuals who felt that they weren't heard. And on one hand, I'm not naive enough to think that I've never left a patient encounter and had that patient not feeling heard. I'm guilty of many of the same things. Sometimes it's nothing that we've done as physicians, it's just you don't develop a rapport with the patient, right? But it made me think and it made me wonder and question, why is there this mismatch? Why are there so many patients who come seeking someone who listens, seeking a solution or a treatment that is maybe not standard, but might be a better fit for them than the standard? As you know, oncology is very algorithmic, and certainly, as many of the the fellows and residents who come into my clinic learn, yes, there are guidelines and yes, there are beautiful flow charts that teach us if you have this cancer, here's the treatment. But for me, that's only half of the practice of oncology. That's the scientific side. We then have the art side, which involves speaking to people, listening to them, seeing them as people, and then trying to fit what we're able to do, the resources we have, with what the patient's goals are, with their wishes or desires are. Mikkael Sekeres: I completely agree with you. I think sometimes patients come to our clinics, to an examination room, and they look at it as a place to be heard, and sometimes a safe space. You'll notice that, if you've been practicing long enough, you'll have some couples who come in and one of our patients will say something and the partner will reflect and say, "Gee, I never heard you say that before. I never knew that." So if people are coming in expecting to be heard in a safe space, it's almost nowhere more important to do that when it comes to treating their cancer also. Beatrice Preti: Yes. And as I say again to many of our learners, different specialties have different tools to treat or help alleviate sickness, illness, and suffering. For example, a surgeon has quite literal tools. They have their hands, they have their eyes, they're cutting, they're performing procedures. By and large, especially in medical oncology, we are quite limited. Certainly I have medications and drugs that I can prescribe, but in the world of GI oncology, often these are not going to lead to a cure. We are talking about survival in the order of months, maybe a year or two if we're very lucky. So the tool that we have and really the biggest, best treatment that we can give to our patients is our words and our time, right? It's those conversations that you have in clinic that really have the therapeutic benefit or potential for someone who is faced with a terminal illness and a poor prognosis more so than any drug or chemotherapy that I can give as a physician. Mikkael Sekeres: I love the notion that our words and our time are our tools for practicing medicine. It's beautiful. You mentioned in your essay three patients who, quote, and you're very deliberate about using the quote, "refused" because it's a loaded term, "refused" recommended medical intervention such as chemotherapy or surgery. Can you tell us about one of them? Beatrice Preti: Ah, well, I would have to be quite vague. Mikkael Sekeres: Of course, respecting HIPAA, of course. We don't want to violate anything. Beatrice Preti: But I think that was another thing too on this day that struck me quite a bit that it was three patients back to back with very similar stories, that they had been seen at other hospitals, they had been seen by other physicians - in one case, I think a couple of different physicians - and had really been offered the choice of, “Here is the standard of care, here is what the guidelines suggest we do, or you can choose to do nothing.” And certainly in the guidelines or in recommended treatment, you know, doublet chemotherapy, triplet therapy, whatever the case may be, this is what's recommended and this is what's standard. But for the patient in front of you, you know, whose goal may be to go to the beach for two months, right? “I don't want to be coming back and forth to the cancer center. Can I take a pill and maybe get blood work a few times while I'm there?” Or you have a patient who says, “You know, I tried the chemotherapy, I just can't do it. It's just too strong. And now they've told me I have to go to hospice if I'm not going to take the recommended treatment.” While in the guideline this may be correct for this patient who's in front of you, there may be another option which is more, in quotes, “correct”, because, is our goal to kill as many cancer cells as we can? Is our goal to shrink the cancer as much as we can? Is our goal even to eke out the maximum survival possible? As an oncologist, I would say no. Our goal is to try to line up what we can do, so the tools, the medications, the chemotherapies, the drugs that we do have in our tool kit, and the symptom medications as well, and line those up with what the patient's goals are, what the patient's wishes are. For many people, I find, when faced with a terminal illness, or faced with an illness with poor prognosis, their goal is not to eke out the last breath possible. They start to look at things like quality of life. They start to look at things like hobbies or travel or spending time with family. And oftentimes, the best way to facilitate that is not by doing the most aggressive treatment. Mikkael Sekeres: In my memory, you evoke an essay that was written for JCO's Art of Oncology by Tim Gilligan called "Knuckleheads" where he had a patient who was, big quotes, "refusing" chemotherapy for a curable cancer. And one of his colleagues referred to the patient as a knucklehead and they asked Tim to see the patient to try to suss out what was going on. And Tim, he used one of our tools. He talked to the person and it turns out he was a seasonal construction worker and it was summer and he was a single dad where the mother of his children wasn't involved in their care at all. And the only way he had to make money during the year was the work he did during the summer because he couldn't work in the winter. So for very primal reasons, he needed to keep working and couldn't take time to take chemotherapy. So they were able to negotiate a path forward that didn't compromise his health, but also didn't compromise his ability to make a living to support his family. But again, like you say, it's that people bring to these interactions stories that we can't even imagine that interfere with our recommendations for how they get cared for. Beatrice Preti: That's a beautiful example of something that I really do try to impress on my learners and my team in general. When someone comes to you and if a recommendation is made or even if they are skeptical about a certain treatment pathway, there is always a ‘why'. One of the challenges and one of the things that comes with experience is trying to uncover or unveil what that ‘why' is because unless you address it and address it head on, it's going to be very difficult to work with it, to work with the patient. So as you said, it's common people have family obligations, job obligations. Oftentimes as well, they have personal experience with certain treatments or certain conditions that they're worried about. Perhaps they had a loved one die on chemotherapy and they're worried about toxicities of chemo. And sometimes you can talk through those things. That needs to be considered, right? When we talk about shared decision-making, you, the patient, and it might be an experience that the patient has had as well that are all in the room that need to be taken into account. Mikkael Sekeres: You invoke the phrase "shared decision-making," which of course, you talk about in your essay. Can you define that for our listeners? What is shared decision-making? Beatrice Preti: Oh, goodness. There are different definitions of this and I am just cringing now because I know that my old teachers will not be happy regardless of what definition I choose. But for me, shared decision-making means that the decision of what to do next, treatment along the cancer journey, etc., is not decided by only one person. So it is not paternalism where I as the physician am making the decision. However, it's not the patient unilaterally making their own decision as well. It's a conversation that has to happen. And oftentimes when I'm counseling patients, I will write down what I see as potential treatment options for this patient and we will go through them one by one with pros and cons. This is usually after an initial bit where I get to know the patient, I ask them what's important to them, who's important in their life, what kind of things do they enjoy doing, and trying to weave that into the counseling and the discussion of the pros and cons. Ultimately, the patient does make the choice, but it's only after this kind of informed consent or this informative process, I guess, so to speak. And for me, that is shared decision-making where it's a conversation that results in the patient making a decision at the end. Mikkael Sekeres: You know, it's so funny you use the word ‘conversation'. I was going to say that shared decision-making implies a conversation, which is one of the reasons I love it. It's not a monologue. It's not just us listening. It's a back and forth until you know, we figure each other out. Beatrice Preti: Yes. Mikkael Sekeres: I wonder if I could ask you one more question. In your essay, you ask the question, "Do we struggle with moral distress when a patient makes a choice that we disagree with based on values that we ourselves do not hold?" Do you think you can answer your own question? Beatrice Preti: So this is getting to my academic work, and my PhD work that we spoke a little bit about in the beginning. I think it's something that we need to be mindful of. Certainly in my training, certainly when I was less experienced, there would be a lot of moral distress because we are not all clones of each other. We are people, but we have our own beliefs, we have our own backgrounds, we have our own experiences. There are times when people, and not just in medicine, but certainly in medicine, certainly patients make decisions that I don't quite understand because they are so different from what I would make or what I would choose for myself or for a family member. On the flip side, I think I've gotten myself, and I've had enough experience at this point in my career, to be able to separate that and say, you know, “But this is someone who has clearly thought things through and based on their own world view, their own perspectives, their own life experiences, this is the choice that's best for them.” And that's certainly something that I can support and I can work with a patient on. But it takes time, right? And it takes very deliberate thought, a lot of mindfulness, a lot of practice to be able to get to that point. Mikkael Sekeres: Well, I think that's a beautiful point to leave off with here. We've been talking to Beatrice Preti, who is an assistant professor at Emory University and an adjunct professor at Western University, and a PhD candidate with Maastricht University to discuss her JCO Oncology Practice article, "No Versus Know: Patient Empowerment Through Shared Decision-Making." Beatrice, thank you so much for joining me today. Beatrice Preti: Absolutely. Mikkael Sekeres: If you've enjoyed this episode, consider sharing it with a friend or a colleague or leave us a review. Your feedback and support helps us continue to have these important conversations. If you're looking for more episodes and context, follow our show on Apple, Spotify, or wherever you listen, and explore more from ASCO at asco.org/podcasts. Until next time, this has been Mikkael Sekeres for JCO Cancer Stories: The Art of Oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Show Notes: Like, share and subscribe so you never miss an episode and leave a rating or review. Guest Bio: Dr Beatrice Preti is an Assistant Professor at Emory University Additional Material: Knuckleheads, by Dr Timothy Gilligan and accompanied podcast episode.  

Despite weeks of whirlwind American diplomacy, Russia sent wave after wave of drones and missiles across Kyiv and other cities on Thursday.It was the fiercest attack on the Ukrainian capital since President Donald Trump and Russian President Vladimir Putin met two weeks ago in Alaska, and the clearest indication yet of the Kremlin's resolve to continue its bombardment of Ukraine, leaving the two sides no closer to securing a diplomatic off-ramp.Host Caryn Ceolin speaks with Oleksa Drachewych, an assistant professor of history at Western University, about the challenges in forging a lasting peace in the largest land war in Europe since World War II. We love feedback at The Big Story, as well as suggestions for future episodes. You can find us:Through email at hello@thebigstorypodcast.ca Or @thebigstoryfpn on Twitter

This recording features audio versions of September 2025 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Interventional Radiology Reporting Standards and Checklist for Artificial Intelligence Research Evaluation (iCARE) ReadPreservation of Fertility by Direct Puncture Embolization of Acquired Uterine Arteriovenous Fistulae in Women of Childbearing Age with Life-Threatening Hemorrhage ReadMagnetic Resonance Imaging-guided Transurethral Ultrasound Ablation (TULSA) of Localized Prostate Cancer: A prospective Trial ReadSafety and Effectiveness of Percutaneous Electrohydraulic and Laser Lithotripsy in the Management of Biliary Stones: The Multicenter National Percutaneous Cholangioscopy Registry ReadDegradable Starch Microsphere Transarterial Chemoembolization as Salvage Therapy in Patients with Uveal Melanoma Liver Metastases ReadHigh-Dose Radioembolization Limited by Lung Shunt for Hepatocellular Carcinoma Supplied by the Inferior Phrenic Artery ReadImpact of Hemodialysis Duration on Arterial Characteristics and Patient Outcomes following Endovascular Therapy for Inframalleolar Occlusive Disease: Results from the MAVERICK Study ReadJVIR and SIR thank all those who helped record this episode. To sign up to help with future episodes, please contact our outreach coordinator at millennie.chen.jvir@gmail.com.Host· Sonya Choe, University of California Riverside School of MedicineAudio Editor· Daniel Roh, Loma Linda University School of MedicineOutreach Coordinator:· Millennie Chen, University of California Riverside School of MedicineAbstract Readers:· Sakeena Siddiq, Western University of Health Sciences, California· Tiffany Nakla, Touro University Nevada College of Osteopathic Medicine, Nevada· Mark Oliinik, Loma Linda University School of Medicine· Nate Wright, Warren Alpert Medical School of Brown University· Daniel Roh,  Loma Linda University School of Medicine· Morgan Smeltzer, Western Michigan University Homer Stryker MD School of Medicine· Thanmayi Parasu, University of Texas Medical Branch Read more about interventional radiology in IR Quarterly magazine or SIR's Patient Center.Support the show Support the show

Ontario Premier Doug Ford says he'll crack down on labs using cats and dogs in experiments after revelations that beagles were subjected to heart attack studies at St. Joseph's Health Care in London, Ontario. The case has ignited debate over the role of animals in science. We hear from animal bioethicist Andrew Fenton, Western University researcher Arthur Brown, and Executive Director of the Canadian Centre for Alternatives to Animal Methods, Charu Chandrasekera, who advocates for replacing animal testing with new technologies.

On today's episode of the Illumination by Modern Campus podcast, podcast host Shauna Cox was joined by Amrit Ahluwalia to discuss the critical shift from access to belonging and the redesign of orientation for adult learners.

Episode 200: All About Ascites.     Jesica Mendoza explains the pathophysiology, diagnosis and management of ascites. Dr. Arreaza adds input about early detection and prevention of spontaneous bacterial peritonitis. Written by Jesica Mendoza, OMS IV, Western University, College of Osteopathic Medicine of the Pacific. Edits and comments by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Welcome to our episode 200! It is an honor to welcome back a wonderful medical student, her name is Jesica, and she has prepared this topic, and she is excited to share this information with us. Jesica presented in June this year an episode about gestational diabetes (episode 193) and today she will talk about ascites. Jesica, please tell us who you are again. What is ascites?Ascites is the buildup of fluid in between the visceral peritoneum and the parietal peritoneum in the abdomen. This is often caused by cirrhosis of the liver due to the increased portal HTN which leads to increased nitrous oxide (NO) and prostaglandins which then causes splanchnic vasodilation and decreased effective arterial volume. The decrease in arterial volume then causes an increase in the renin–angiotensin–aldosterone system (RAAS) and antidiuretic hormone (ADH) from the renal system which leads to sodium and water retention. This then causes a net reabsorption of fluids and ascites.Evaluation of ascites.Once someone has been found to have ascites the next step will be a diagnostic paracentesis. This includes removing fluid from the peritoneal cavity in order to determine the SAAG (Serum Ascites Albumin Gradient) score. SAAG : (serum albumin) − (albumin level of ascitic fluid). The two values should be measured at the same time.This score helps determine the cause of the ascites with a score >1.1 g/dL indicating portal hypertension usually due to liver disease such as cirrhosis. A SAAG score of 250 PMNS/mL. Fluid should be sent to the lab for culture and then antibiotics should be started. IV 3rd generation cephalosporins are typically used. Fluoroquinolones are also used to prevent the recurrence of SBP.If you desire to learn more about SBP, listen to our episode 123. By the way, propranolol is a frequently used medication to prevent GI bleeding from esophageal varices in cirrhosis and also to decrease the development of ascites. It should be used in patients who have compensated cirrhosis and must be avoided in patients with refractory ascites, hypotension, renal dysfunction or active infection. So, to wrap things up we should remember that once we identify ascites with our physical exam of the patient, we should make sure to obtain a paracentesis as these results will be the main guide for our treatment. The treatment can then range from medical treatment such as spironolactone and/or loop diuretics to TIPS procedures, PleurX or even liver transplant. Always be on the lookout for SBP in patients with ascites and always remember to obtain a culture on the ascitic fluid prior to starting antibiotics. Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Ascites, Cleveland Clinic, https://my.clevelandclinic.org/health/diseases/14792-ascites.Huang LL, Xia HH, Zhu SL. Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites. J Clin Transl Hepatol. 2014 Mar;2(1):58-64. doi: 10.14218/JCTH.2013.00010. Epub 2014 Mar 15. PMID: 26357618; PMCID: PMC4521252. https://pmc.ncbi.nlm.nih.gov/articles/PMC4521252/.Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

In this episode, we speak with Rob Arntfield MD, the emergency medicine and critical care physician who founded Deep Breathe, an AI company whose technology actually surpassed doctors in COVID-19 lung ultrasound diagnosis. Rob shares his journey of merging computer science roots with medical expertise during the pandemic to create breakthrough diagnostic technology. Rob is a self-described "acutivist" working as an emergency medicine and critical care physician at London Health Sciences Centre. He serves as Professor of Medicine at Western University and co-authored the textbook Point-of-Care Ultrasound. Website: https://www.deepbreathe.ai/ If you enjoy the show, please leave a ⭐⭐⭐⭐⭐ rating on Apple or a

Recently, US Secretary of State Marco Rubio imposed sanctions on the UN Special Rapporteur on the Occupied Palestinian Territories, Francesca Albanese, saying, “The United States has repeatedly condemned and objected to biased and malicious activities of Albanese that have long made her unfit for service as a Special Rapporteur.”  Today we are joined by three of Albanese's predecessors—John Dugard, Richard Falk, and Michael Lynk, who talk about what these sanctions mean. They trace the United States' and Israel's longstanding attacks on not only Special Rapporteurs on Palestine, but the very claims to Palestinian rights. This latest instance is a particularly egregious attack on the UN and international law. We end with a plea to the international community to come to the aid of the Palestinian people, who are suffering famine, disease, and warfare of immense proportions.John Dugard SC, Emeritus Professor of Law, Universities of the Witwatersrand and Leiden; Member of Institut de Droit International; ; Director of Lauterpacht Centre for International Law, Cambridge (1995-1997); Judge ad hoc  International Court of Justice (2000-2018); Member of UN International Law Commission (1997 -2011); UN Special Rapporteur on Situation of Human Rights in Occupied Palestinian Territory (2001-2008); Legal Counsel, South Africa v Israel (Genocide Convention).Richard Falk is Albert G. Milbank Professor Emeritus of International Law at Princeton University (1961-2001) and Chair of Global Law, Faculty of Law, Queen Mary University London. Since 2002 has been a Research Fellow at the Orfalea Center of Global and International Studies at the University of California, Santa Barbara. Between 2008 and 2014 he served as UN Special Rapporteur on Israeli Violations of Human Rights in Occupied Palestine.Falk has advocated and written widely about ‘nations' that are captive within existing states, including Palestine, Kashmir, Western Sahara, Catalonia, Dombas.Falk has been nominated for the Nobel Peace Prize several times since 2008.Michael Lynk was a member of the Faculty of Law, Western University, London, Ontario, Canada between 1999 and his retirement in 2022. He taught courses in labour, human rights, disability, constitutional and administrative law. He served as Associate Dean of the Faculty between 2008-11. He became Professor Emeritus in 2023.In March 2016, the United Nations Human Rights Council unanimously selected Professor Lynk for a six-year term as the 7th Special Rapporteur for the human rights situation in the Palestinian Territory occupied since 1967. He completed his term in April 2022.He has written about his UN experiences in a 2022 book co-authored with Richard Falk and John Dugard, two of his predecessors as UN special rapporteurs: Protecting Human Rights in Occupied Palestine: Working Through the United Nations (Clarity Press).Professor Lynk's academic scholarship and his United Nations reports have been cited by the Supreme Court of Canada, the International Court of Justice, the International Criminal Court and the United Nations General Assembly.  

China hits Canadian canola with 75.8% anti-dumping tariff, raising stakes in ongoing trade dispute (0:45) Guest: Mackenzie Gray, Global News Ottawa correspondent As U.S. auto exports sink, could car prices soon skyrocket? (10:21) Guest: Jeremy Cato, Automotive Journalist at CatoCarGuy.com From swiping to sidetracked: Social media and the vanishing attention span (21:22) Guest: Dr. Emma Duerden, Associate Professor at Western University's Faculty of Education, and Canada Research Chair in Neuroscience and Learning Disorders Cowichan land claim ruling and the future of property rights in B.C. (33:09) Guest: Richard Zussman, Global B.C. Legislative Bureau reporter Learn more about your ad choices. Visit megaphone.fm/adchoices

Israel's security cabinet approved a plan to take control of Gaza city. Michael Lynk is a professor emeritus of law at Western University and the former UN Special Rapporteur for human rights in the occupied Palestinian territory. He shares his thoughts on this move with Jeff Douglas and gives us an update of what is happening in Gaza.

What happens when two siblings challenge themselves to grow as leaders together?In this episode of the Leaders of Tomorrow podcast, host Chris Thomson sits down with Adriana and Cole Benoit, two exceptional student leaders who have thrived in the Student Works Management Program. What started as a summer job turned into a transformational journey of self-discovery, confidence, and leadership development.Adriana opens up about how the program helped her overcome shyness, develop independence, and build lasting people skills that have shaped her both personally and professionally. Meanwhile, Cole shares the mindset shifts he experienced as a coach and operator, learning how to inspire accountability and scale a team of responsible leaders.Together, they reflect on the personal growth, business lessons, and family support that fueled their success. If you're considering the Student Works Program or want a deeper look at how it shapes young entrepreneurs, this episode offers an inspiring window into what's possible when you commit to becoming your best self.Enjoy!Key takeawaysHow the Student Works Program builds confidence and independenceHow Adriana overcame shyness and started taking ownership of her lifeWhy coaching others to take accountability is key to scaling a teamThe emotional and mental challenges of running a student businessHow leadership creates ripple effects year after yearWhy alignment between personal goals and team goals drives successWhy Adriana and Cole feel more confident about their futures than ever beforeAnd much more...Guest Bios:Adriana grew up immersed in athletics, excelling in gymnastics, figure skating, and rugby, and developing leadership skills through coaching and camp counselling. At the University of Guelph, she joined the Varsity Cheerleading team and began working with Student Works, first as a window cleaner and later as a franchise manager. Over three years, she ran a successful business producing nearly $450,000 in revenue, employing over 40 students, and serving more than 750 clients. A top performer, she is transitioning into a Business Coach role in 2024 to mentor students in running their own businesses.Cole is a dedicated Consumer Behaviour student at Western University with hands-on experience in sales, marketing, and management. Through the Student Works Management Program and other ventures, he has honed his skills in cold-calling, sales, client relations, recruitment, employee management, and project planning. Running his own service business continues to challenge and develop him professionally.Resources:Student WorksDisclaimer:The views, information, or opinions expressed during this podcast are solely those of the individuals involved and do not necessarily represent those of Leaders of Tomorrow podcast or its affiliates. The content provided is for informational and entertainment purposes only and is not intended to be a substitute for professional advice. We make no representations as to the accuracy, completeness, suitability, or validity of any information on this podcast and will not be liable for any errors, omissions, or delays in this information or any losses, injuries, or damages arising from its display or use. Listeners should consult with a professional for specific advice tailored to their situation. By accessing this podcast, you acknowledge that any reliance on the content is at your own risk.

Karl Stelter is a filmmaker whose commercial director / producer work has been recognized by  the Clio's, Tribeca, Tribeca X, the ADDY's, Telly's, Webby's, 1.4, ADCC, DUST, and over 15 Oscar Qualifying film festivals.  His recent Jury Award win at Sebastopol qualified him for the 2025 Oscars. His clients include Invisalign, Amazon, NFL, Telus, Western University of Health Sciences, and GHA Autism Supports among others.Today we get into how Karl convinced brands like Telus and Invisalign to buy documentary projects he was already making as passion projects and turn them into commercials and branded entertainment, how to make the most of a festival experience like Tribeca and how to pivot into a new type of work that's different from what you've already built a portfolio in. BREAKDOWN: 2:43 – two(!) projects at Tribeca, both scripted and branded doc spot3:03 – Swimming with Butterflies feat. Brand partner, Invisalign and TribecaX3:53 – Balancing authentic story x branded, paying the bills x passionate5:23 – Karl's journey with the subject of the doc, Paralympic swimmer9:03 – Gaining trust with documentary subjects11:43 – Shooting underwater feat. DP Joe Simon12:33 – Pitching a short doc to a brand (Invisalign)16:33 – How much would a brand give as a budget?19:13 – did Invisalign care about where the spot would live?20:13 – Submitting to Tribeca documentary vs. TribecaX (branded counterpart)21:38 – The Tribeca experience22:53 – The Lord of All Future Space and Time: a maximalist cheesecake short film (rich & dense)24:38 – repeat collaborators27:23 – running his own production company, Journeyman Studios, since 201229:48 – Pivoting from weddings to corporate videos; how to pivot to new types of work32:23 – don't lose sight of your artistic side34:08 – success in the industry is a game of time37:05 – getting into a top tier festival while simultaneously being rejected from much less prestigious festivals38:23 – realistic acceptance rate for festivals39:08 – Pitching: collaborators and clients42:53 – don't lose your collaborators to be right44:28 – how to enjoy Tribeca47:28 – different financing models: Karl's other shorts!57:38 – how to have a family as a filmmaker1:07:13 – TIME CAPSULE

In this week's episode of the Real Integrative Medicine podcast, Dr. Jordan Robertson and Dr. Keara Taylor delve into the complexities of PMS and PMDD, exploring the emotional and physical symptoms often associated with these conditions. They discuss the importance of understanding hormonal fluctuations, the role of lifestyle changes, and the various treatment options available, including both medical and natural approaches. Dr. Taylor shares insights on the latest research and the importance of personalized treatment plans for women experiencing PMS.----Dr. Keara Taylor is a Naturopathic Doctor with a clinical focus in women's hormonal health, supporting patients with PMS, PCOS, period problems, perimenopause, and menopause. As a Menopause Society Certified Practitioner (formerly NAMS), she is dedicated to providing comprehensive, evidence-based care to guide women through their hormonal transitions with confidence and ease. A lifelong learner with a deep curiosity for health and wellness, Dr. Keara's path to patient care wasn't straightforward—she spent six years as a Chartered Accountant before discovering her true passion. Now, she's on a mission to cut through the noise of online misinformation and provide her patients with clear, evidence-based solutions. Dr. Keara holds a Doctor of Naturopathy from the Canadian College of Naturopathic Medicine and an Honours Bachelor of Health Sciences from Western University. Outside of practice, Dr. Keara can be found buried in a book or outdoors with her family, skiing, playing tennis, or swimming in the lake.Follow Dr. Keara on Instagram Discover Dr. Taylor's Course----Dr. Jordan Robertson is a leader in naturopathic and integrative medicine. She is dedicated to evidence-based healthcare and founded The Confident Clinician, which empowers practitioners with up-to-date research and practical tools. With over 15 years in clinical practice and experience teaching at McMaster University's Health Sciences program, she bridges the gap between research and real-world application.Follow Dr. Jordan on Instagram----Do you ever wish there were a knowledge base built just for you?Have you searched for a resource that supported you so you could focus on what really matters for your business?The Confident Clinician is the ONLY medical knowledge base built for integrative practitioners.Over 750 clinician members have simplified their patient care by using our knowledge base and exclusive members-only education.Our knowledge base and clinical topics are updated on an ongoing basis and, and we offer exclusive members-only courses that support you, whatever your clinical focus.Ready to be supported in your work?Learn More About The Confident Clinician HereDiscover The Confident Clinician's 5-Day AI Smart-Search ChallengeWant to dive deeper? Explore the latest research breakdowns and practical tools on our blog----Thank you for listening. Please subscribe and share.

hat is the relationship between culture and trade? In Trading on Art: Cultural Diplomacy and Free Trade in North America Sarah E. K. Smith, an Associate Professor in the Faculty of Information and Media Studies at Western University and the Canada Research Chair (Tier 2) in Art, Culture and Global Relations, examines the history of cultural relations between Canada, the USA and Mexico at the turn of the twenty-first century. The book considers how North America was conceptualised by cultural practices such as art and video, as well as how the arts engaged and responded to free trade agreements in that period. As the world confronts a very different trading and cultural context, the book is essential reading for anyone interested in the future, as well as the past, of cross-national cultural exchange. The book will also be available open access in 2026 Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/american-studies

hat is the relationship between culture and trade? In Trading on Art: Cultural Diplomacy and Free Trade in North America Sarah E. K. Smith, an Associate Professor in the Faculty of Information and Media Studies at Western University and the Canada Research Chair (Tier 2) in Art, Culture and Global Relations, examines the history of cultural relations between Canada, the USA and Mexico at the turn of the twenty-first century. The book considers how North America was conceptualised by cultural practices such as art and video, as well as how the arts engaged and responded to free trade agreements in that period. As the world confronts a very different trading and cultural context, the book is essential reading for anyone interested in the future, as well as the past, of cross-national cultural exchange. The book will also be available open access in 2026 Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

hat is the relationship between culture and trade? In Trading on Art: Cultural Diplomacy and Free Trade in North America Sarah E. K. Smith, an Associate Professor in the Faculty of Information and Media Studies at Western University and the Canada Research Chair (Tier 2) in Art, Culture and Global Relations, examines the history of cultural relations between Canada, the USA and Mexico at the turn of the twenty-first century. The book considers how North America was conceptualised by cultural practices such as art and video, as well as how the arts engaged and responded to free trade agreements in that period. As the world confronts a very different trading and cultural context, the book is essential reading for anyone interested in the future, as well as the past, of cross-national cultural exchange. The book will also be available open access in 2026 Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/critical-theory

hat is the relationship between culture and trade? In Trading on Art: Cultural Diplomacy and Free Trade in North America Sarah E. K. Smith, an Associate Professor in the Faculty of Information and Media Studies at Western University and the Canada Research Chair (Tier 2) in Art, Culture and Global Relations, examines the history of cultural relations between Canada, the USA and Mexico at the turn of the twenty-first century. The book considers how North America was conceptualised by cultural practices such as art and video, as well as how the arts engaged and responded to free trade agreements in that period. As the world confronts a very different trading and cultural context, the book is essential reading for anyone interested in the future, as well as the past, of cross-national cultural exchange. The book will also be available open access in 2026 Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/performing-arts

hat is the relationship between culture and trade? In Trading on Art: Cultural Diplomacy and Free Trade in North America Sarah E. K. Smith, an Associate Professor in the Faculty of Information and Media Studies at Western University and the Canada Research Chair (Tier 2) in Art, Culture and Global Relations, examines the history of cultural relations between Canada, the USA and Mexico at the turn of the twenty-first century. The book considers how North America was conceptualised by cultural practices such as art and video, as well as how the arts engaged and responded to free trade agreements in that period. As the world confronts a very different trading and cultural context, the book is essential reading for anyone interested in the future, as well as the past, of cross-national cultural exchange. The book will also be available open access in 2026 Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/art

hat is the relationship between culture and trade? In Trading on Art: Cultural Diplomacy and Free Trade in North America Sarah E. K. Smith, an Associate Professor in the Faculty of Information and Media Studies at Western University and the Canada Research Chair (Tier 2) in Art, Culture and Global Relations, examines the history of cultural relations between Canada, the USA and Mexico at the turn of the twenty-first century. The book considers how North America was conceptualised by cultural practices such as art and video, as well as how the arts engaged and responded to free trade agreements in that period. As the world confronts a very different trading and cultural context, the book is essential reading for anyone interested in the future, as well as the past, of cross-national cultural exchange. The book will also be available open access in 2026 Learn more about your ad choices. Visit megaphone.fm/adchoices

hat is the relationship between culture and trade? In Trading on Art: Cultural Diplomacy and Free Trade in North America Sarah E. K. Smith, an Associate Professor in the Faculty of Information and Media Studies at Western University and the Canada Research Chair (Tier 2) in Art, Culture and Global Relations, examines the history of cultural relations between Canada, the USA and Mexico at the turn of the twenty-first century. The book considers how North America was conceptualised by cultural practices such as art and video, as well as how the arts engaged and responded to free trade agreements in that period. As the world confronts a very different trading and cultural context, the book is essential reading for anyone interested in the future, as well as the past, of cross-national cultural exchange. The book will also be available open access in 2026 Learn more about your ad choices. Visit megaphone.fm/adchoices

The Herle Burly was created by Air Quotes Media with support from our presenting sponsor TELUS, as well as CN Rail.Greetings, you curiouser and curiouser Herle Burly-ites! Last week on the pod, we had Scott Aitchison on – Conservative Housing Critic. This week we're sticking with that theme – housing – so central to the last federal election and something I want to keep exploring with you.So on the pod today I want to look it at from a couple of perspectives. Experience on the ground and policy making. What's the current state of play in the market?  What's been the impact of measures to date? Has the situation improved?  How does the condo glut affect things?  And broadly, is the government plan a good one?We've assembled a housing panel to help answer those questions: Ron Butler + Mike Moffatt + Tyler Meredith!Ron Butler describes himself as a “big, old, overly opinionated mortgage broker, worried about the future of housing for average Canadians.” He's the founder of Butler Mortgage Inc, with over 30 years in the business.  And hosts of his own weekly pod, “The Angry Mortgage Podcast”, where he swears a f**k of a lot and shares his insights about the industry.Mike Moffatt is co-host of the “Missing Middle Podcast.”  His twitter bio says he's a Husband, Father, Brother, Son, Economist and Housing Guy. Among other things, he's an Assistant Professor in the Business, Economics, and Public Policy Group at Ivey Business School, Western University. He served as Director of Policy and Research at Canada 2020. And he's done extensive research on Canada's housing supply and the affordability crisis. Tyler Meredith is the former Head of Fiscal and Economic Policy for Prime Minister Trudeau and Ministers of Finance, Chrystia Freeland and Bill Morneau. Today, he's a Founding Partner at Meredith/Boessenkool Policy Advisors. And he was a co-host of the limited run podcast “Race to Replace”, right here at Air Quotes Media!Thank you for joining us on #TheHerleBurly podcast. Please take a moment to give us a rating and review on iTunes, Spotify, Stitcher, Google Podcasts or your favourite podcast app.Watch episodes of The Herle Burly via Air Quotes Media on YouTube.The sponsored ads contained in the podcast are the expressed views of the sponsor and not those of the publisher.

This recording features audio versions of August 2025 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Transarterial Embolization for Pulmonary Arteriovenous Malformation: A Systematic Review and Meta-Analysis ReadTransperineal MR Imaging–Guided Prostate Biopsy: A Prospective Randomized Controlled Study on Safety and Effectiveness Compared with Transrectal Biopsy ReadHistopathologic Response and Oncologic Outcomes after Segmental and Subsegmental Transarterial Chemoembolization and Radioembolization for Hepatocellular Carcinoma ReadClinical Effectiveness and Safety of Radiofrequency Ablation Combined with Percutaneous Osteoplasty in the Management of Pubic Skeletal Metastases ReadSingle-Center Experience of Portal Vein Recanalization and Transjugular Intrahepatic Shunt Placement in Patients with Portovisceral Thrombosis ReadTransjugular Splenocaval Shunt Creation for the Treatment of Portal Vein Cavernous Transformation with Recurrent Variceal Hemorrhage ReadJVIR and SIR thank all those who helped record this episode. To sign up to help with future episodes, please contact our outreach coordinator at millennie.chen.jvir@gmail.com.Host· Sonya Choe, University of California Riverside School of MedicineAudio editor· Sanya Dhama, University of California Riverside School of MedicineOutreach coordinator:· Millennie Chen, University of California Riverside School of MedicineAbstract readers:· Emily Jagenburg, Oakland University William Beaumont School of Medicine· Shobhit Chamoli, Armed Forces Medical College, Pune, India· Char Rai, Western University of Health Sciences College of Osteopathic Medicine· Andrea Serrato,  University of California Riverside School of Medicine· Andrew Sasser, University of Miami Miller School of Medicine, Florida· Ipek Midillioglu, Western University of Health Sciences, College of Osteopathic Medicine, California Read more about interventional radiology in IR Quarterly magazine or SIR's Patient Center. Support the show

From club rejections to a BMO Capital Markets investment-banking offer—Devin's grind is the blueprint. The Western University (Ivey) sophomore fired off 412 cold emails, converted 60 coffee chats, cracked 9 first-rounds and juggled 4 super-days in a single week to secure his dream 2026 IB internship. Hear how WSO Academy's resume overhaul, bootcamps and rapid-fire mock interviews super-charged his preparation and confidence. Perfect watch if you're targeting Toronto's Big Five or NYC banks and need a proven networking playbook. ------------------------------------------------------------------------------------------------------

Welcome to Episode 263 of Autism Parenting Secrets.This week, I'm joined by Nicole Rincon.She's a board-certified Physician Assistant and an all-in mom of 13-year-old triplets.Her unique vantage point—as both a medical professional and a parent on a healing mission—makes this conversation essential listening.Nicole's journey wasn't easy. One of her sons became completely non-verbal, and her daughter began having seizures. But today, all three of her children are thriving.She didn't wait for certainty—she took bold, informed steps.And what she reveals in this episode will resonate deeply with any parent seeking real answers.The secret this week is…Take 3 VITAL StepsYou'll Discover:Nicole's Story of Regression - and What Most Doctors Missed (3:34)The Unique Root Causes for Each of Her Three Children (9:19)Vital Step #1 (13:04) Vital Step #2 (17:13)Vital Step #3 (30:00) Nicole's One Belief That Fuels Her Unwavering Commitment (41:01)About Our Guest:Nicole Rincon, MS, PA-C, is a board-certified Physician Assistant with a Master's in Physician Assistant Studies from Western University of Health Sciences. She practices at Rossignol Medical Center, specializing in integrative and functional approaches for children with special needs. As a mother to triplets—two of whom regressed into autism—Nicole's life changed forever. Her boys are now thriving thanks to personalized interventions, and her daughter has been seizure-free for over a decade. Nicole's passion is empowering families to pursue healing and not give up hope.https://www.nicolerincon.com/abouthttps://rossignolmedicalcenter.com/doctors/nicole-rincon/ References In This Episode:Common Testing and Treatments for Newly Diagnosed Patients with Autism, Nicole Rincon at TACA Now Conference, October 2019Uncommon Living: Episode 5: Mitochondrial Therapies for Autism With Nicole RinconAutism Parenting Secrets, Episode 245, EVIDENCE-BASED Treatments FIRST with Dr. Richard FryeAdditional Resources:To learn more about personalized 1:1 support, go to www.elevatehowyounavigate.comTake The Quiz: What's YOUR Top Autism Parenting Blindspot?If you enjoyed this episode, share it with your friends.

Dr. Renee Coffman is president and co-founder of the Nevada College of Pharmacy, now Roseman University of Health Sciences. She previously served as the University's Executive Vice President for Quality Assurance and Intercampus Consistency and the Dean of its College of Pharmacy. Before establishing Roseman University, Dr. Coffman became a founding member of the faculty at Western University of Health Sciences, where she also held the position of Facilitative Officer for Student Services. While at Western, Dr. Coffman and four colleagues received Honorable Mention for the AACP Innovations in Teaching Awards. A licensed pharmacist in the state of Nevada, Dr. Coffman earned a Pharmacy degree from OhioNorthern University in 1987 and, following graduation, worked as a pharmacist in her hometown of Bucyrus, Ohio and in Piqua, Ohio. In 1995, Dr. Coffman earned a doctoral degree in Industrial and Physical Pharmacy from Purdue University, where she received the Kienle Award for Excellence in Teaching, the Jenkins-Knevel Award for Outstanding Graduate Research, and was awarded an AAPE-AFPE Association Fellowship in Pharmaceutical Sciences.Dr. Coffman is a member of the American Association of Colleges of Pharmacy, American Pharmaceutical Association, American Association of Pharmaceutical Scientists, the American Society of Health System Pharmacists, and the International Federation of Pharmacy, as well as Phi Kappa Phi and Rho Chi Honor Societies and the Phi Lambda Sigma Pharmacy Leadership Society. Dr. Coffman has worked to support pharmacy, education, and improved health care through herwork with the Southern Nevada Medical Industry Coalition, iDO (Improving Diabetes and Obesity inSouthern Nevada), the Nevada State Board of Pharmacy Medication Error Discussion Group, and theNevada State Board of Pharmacy Committee on Standards for Approval of Pharmacy Technician Training Programs. Additionally, Dr. Coffman was instrumental in successful legislative efforts permitting pharmacists to perform finger-stick blood glucose testing. In recognition of her community service in Southern Nevada, in 2008, she received the “Who's Who in Healthcare” Award and the “Women of Distinction” Award, both sponsored by In Business Las Vegas, now VEGAS INC. In 2017, the publication recognized Dr. Coffman as one of 12 “Women to Watch” in business. In 2012, she was named a “Distinguished Alumnus” by Ohio Northern University and in 2021 was named a “Distinguished Alumnus” by Purdue University.

On this Canada Day, we're reflecting on our national identity – but dependent on who you ask, you'll get a different answer. Being Canadian comes with a complex mix of opinion, taking into account politics, history and geography. Are we still considered the polite neighbours to the north? Are we more united as a country since our sovereignty has been threatened by President Donald Trump? Host Melanie Ng reflects on these questions and more with Howard Ramos, a political sociologist at Western University.We love feedback at The Big Story, as well as suggestions for future episodes. You can find us: Through email at hello@thebigstorypodcast.ca  Or @thebigstoryfpn on Twitter

Even in the name of love, we can justify hatred, even murder, of the other. But why do we hate others? Scholars have identified a list of 10 reasons why one group may hate another group. They also have suggestions on how to break the cycle of hate. Guests in this episode are scholars from the Canadian Institute for Advanced Research (CIFAR):Prerna Singh, professor of political science, Brown University, U.S.Victoria Esses, professor of psychology, Western University, London, Ontario Stephen Reicher, professor of social psychology, University of St. Andrews, Scotland